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Excessive synthesis and storage of lipids is a prominent feature of the 
current epidemic of metabolic disorders, including obesity, diabetes and non-
alcoholic fatty liver disease (NAFLD).  Upon feeding, fatty acids and triglycerides 
are synthesized primarily in the liver in response to insulin signaling. This process 
is mediated by the sterol regulatory element binding protein 1c (SREBP-1c) 
transcription factor, a principal regulator of lipogenesis. Upon activation, SREBP-
1c stimulates the transcription of the key lipogenic enzymes that catalyze the 
synthesis of fatty acids and their esterification to triacylglycerides.  
Hyperactivation of SREBP-1c has been implicated in promoting pathologic fat 
synthesis and driving features of the metabolic syndrome, including hepatic lipid 
accumulation (steatosis), dyslipidemia and insulin resistance. 
PAS kinase (PASK) is an evolutionarily conserved serine/threonine kinase 
that has been proposed to function as a nutrient-responsive metabolic regulator. 
Pask-/- mice are resistant to high fat diet-induced metabolic disorders. 
Interestingly, Pask-/- mice exhibited almost complete protection from hepatic 
steatosis, but the mechanism underlying this phenotype was unknown. Here, we 
show that PASK promotes hepatic lipogenesis by activating SREBP-1c. This 
regulation occurs at the proteolytic maturation step of SREBP-1c, where the 






cleavages to liberate the transcriptionally active fragment of the protein. SREBP-
1c maturation is strongly induced by feeding and insulin signaling, a condition 
that also stimulates the hepatic expression of PASK. Using genetic and 
pharmacological approaches, we demonstrate that PASK is required for SREBP-
1c maturation in response to feeding and insulin stimulation. Inhibition of PASK 
results in decreased expression of the lipogenic SREBP-1c target genes and 
reduced lipid production in cultured cells and in the mouse and rat liver. 
Importantly, administration of a PASK inhibitor not only improves hepatic 
steatosis and whole-body dyslipidemia, but also partially reverses insulin 
resistance in animal models of diet-induced obesity and dyslipidemia, indicating 
that PASK is a potential therapeutic target for metabolic diseases. These studies 
not only further our understanding of the physiological functions of PASK, but 
also provide new insight into the pathogenesis and treatment of NAFLD and 
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1.1 Per-Arnt-Sim (PAS) Kinase 
PAS kinase (PASK) is a protein kinase that is conserved from yeast to 
human. It was first identified through a sequence homology search against the 
Bradyrhizobium japonicum FixL PAS domain, and was subsequently cloned from 
HeLa cells (Rutter et al., 2001). All PASK orthologs are composed of an N-
terminal PAS domain and a C-terminal serine/threonine kinase domain. 
 
1.1.1 PAS Domain 
PAS domains are named after Period (Per), Aryl hydrocarbon nuclear 
receptor (Arnt) and Single-minded (Sim) proteins in which these domains were 
first identified (Nambu et al., 1991). The PAS domain is found in a wide variety of 
proteins across phyla, including transcriptions factors, ion channels and kinases 
(Sabatini and Lynn, 2015). PAS domains commonly function as sensory domains 
for extra- and intracellular stimuli, such as oxygen, redox state and light (Zhulin et 
al., 1997). Despite the divergent primary sequences among these proteins, PAS 
domains adopt a broadly conserved core structure that is composed of a five-
stranded antiparallel β-sheet flanked by several α-helices (Taylor and Zhulin, 
1999). Most PAS domains are known to contain a central hydrophobic pocket at 
the core of their structure, which enable them to bind a variety of small ligands, 
including ATP, heme and flavins (Kitanishi et al., 2008; Monson et al., 1995; 
Soshilov and Denison, 2008; Stephenson and Hoch, 2001). Sensory information 
from PAS domains is then relayed via attached effector domains, which leads to 
a corresponding physiological output.  
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The PAS domain of PASK shares a similar structure with other PAS 
domains, suggesting possible functional conservation as a sensory module 
(Amezcua et al., 2002). The physiological ligand(s) of the PASK PAS domain 
remains uncharacterized, but in vitro compound screening showed that the PAS 
domain was able to bind small organic molecules in a selective manner 
(Amezcua et al., 2002). Moreover, mutations of residues within the ligand-binding 
pocket that mimic the ligand-bound state of the PAS domain resulted in 
increased activity of PASK in vitro. Compared to the full-length PASK, the kinase 
domain of PASK alone has much higher kinase activity, which can be 
suppressed by adding the purified PAS domain in trans (Rutter et al., 2001). 
These results suggest an overall model where the PAS domain could bind and 
maintain the kinase domain in an inactive state (Figure 1-1). The binding of a 
ligand to the PAS domain could disrupt this inhibitory interaction, thereby 
restoring the kinase activity. This unique feature of PASK also raises an 
interesting hypothesis in which PASK could sense changes in the cellular 
environment (such as in nutrients, energy level) via binding of metabolites to the 
PAS domain, and pass on the signal via phosphorylation of its downstream 
targets, which then leads to appropriate physiological adaptations. 
 
1.1.2 Kinase Domain 
PASK belongs to the calcium/calmodulin-dependent protein kinase (CAMK) 
protein kinase family. The C-terminus of PASK contains a canonical 








Figure 1-1. PAS kinase function in S. cerevisiae. In response to cell integrity 
stress, Psk2 phosphorylates Ugp1 (p-Ugp1) and triggers its translocation from 
cytosol to cell periphery, thus causing the redirection of cellular glucose flux from 
storage towards cell wall synthesis. Psk1 is activated by Snf1 under glucose-
depleted conditions (nonfermentative carbon source). Upon activation, Psk1 
phosphorylates and activates Pbp1, which inhibits TORC1 via stress granule 























































domain of PASK upon signaling, and most likely mediates its cellular effect via 
phosphorylation of its substrates (Cardon and Rutter, 2012). Structural and 
biochemical studies have revealed several unique features of the kinase domain 
of PASK (Kikani et al., 2010). Most protein kinases require phosphorylation on 
one or more residues in the activation loop, a conserved loop motif within the 
kinase domain, to be converted from an inactive to an active form (Johnson et al., 
1996). Most PASK orthologs contain a phosphorylatable threonine residue 
(T1161) within its activation loop. However, phosphorylation at this residue is not 
required for activation of PASK, as evidenced by no difference in 
autophosphorylation or substrate phosphorylation between the wild-type and the 
threonine to alanine (T1161A) mutant form of human PASK. Interestingly, the two 
S. cerevisiae PASK orthologs, which have a valine residue at this position, are 
catalytically active as well. Although activation loop phosphorylation is 
dispensable for basal activity of PASK, it is possible that such phosphorylation 
may become important in regulating PASK activity under certain conditions. 
Another unique feature of the PASK kinase domain lies in the substrate 
specificity. Using peptide library screening, we have determined the consensus 
phosphorylation sequence for human PASK (H/K/R-X-K/R-X-X-*S/*T, where 
*S/*T is the target residue, and X is any amino acid) (Kikani et al., 2010). The 
preference for a histidine residue at the -5 site is unusual among serine/threonine 
kinases, and has only been observed in two other kinases, human large tumor 
suppressor kinase (LATS) (Hao et al., 2008) and its yeast homolog Cbk1 
(Mazanka et al., 2008). The consensus sequence identified for human PASK 
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substrates matches the phosphorylation motif of UDP-glucose 
pyrophosphorylase 1 (Ugp1) (6-HTKTHS*-11), a bona fide substrate of PASK in 
S. cerevisiae (Rutter et al., 2002). This suggests that all PASK orthologs share 
common substrate specificity, which may be instructive in identifying new PASK 
substrates.  
 
 1.1.3 PAS Kinase Function in S. cerevisiae 
There are two PASK paralogs in S. cerevisiae, PSK1 and PSK2 (Rutter et 
al., 2002). They are highly similar in sequence and partially redundant in function. 
Proteomic, genetic and biochemical studies over the years have provided 
evidence that PASK regulates multiple cellular processes in response to 
environmental changes (Figure 1-1). 
 
1.1.3.1 PAS Kinase and Glucose Partitioning 
Genetic and biochemical studies in yeast have established a role for 
PASK in regulating glucose partitioning in response to alterations in the cellular 
environment. Yeast PASK is activated upon cell integrity stress, which can be 
induced by heat shock or detergent treatment to the cells (Smith and Rutter, 
2007). Alternatively, overexpression of Wsc1, a membrane stress sensory protein, 
also activates yeast PASK (Grose et al., 2009), potentially by mimicking the 
stress response. The exact mechanism of how cell integrity stress activates 
PASK remains unclear. Nonetheless, upon activation, PASK directly 
phosphorylates Ugp1 at the serine-11 residue within the consensus sequence 
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described above (Rutter et al., 2002). Ugp1 is an enzyme that converts UTP and 
glucose-1-phosphate to UDP-glucose, which is the primary glucose donor for the 
production of glycogen, the major storage form of glucose, and glucan, the major 
structural constituent of the yeast cell wall (Daran et al., 1995). Interestingly, 
PASK phosphorylation of Ugp1 does not affect its enzymatic activity, but rather 
triggers a conformational change of the enzyme and its recruitment to the cell 
periphery, where cell wall synthesis takes place (Smith and Rutter, 2007). As a 
result, UDP-glucose generated by phosphorylated Ugp1 is mainly used to 
produce cell wall glucan. Consistent with this model, PASK null strain (psk1Δ 
psk2Δ) showed hyperaccumulation of glycogen as well as increased sensitivity to 
cell integrity stress compared to the wild-type strain. Taken together, these 
results establish a model where, in response to cell integrity stress, PASK directs 
glucose flux towards glucan synthesis at the expense of glycogen storage, which 
promotes cell wall stabilization and cell survival. 
Glucose is the preferred carbon source for yeast, which they can ferment 
into ethanol. When the glucose level decreases, yeast must switch to utilize other 
carbon sources for continuous growth. In addition to cell integrity stress, yeast 
PASK is also activated by nonfermentative carbon sources (Grose et al., 2009). 
This activation is dependent on Snf1, the yeast homolog of mammalian AMPK. 
Snf1 is activated under glucose-depleted conditions, which then activates PASK, 
potentially by direct phosphorylation (discussed below) (DeMille et al., 2015). 
Activation of PASK under this condition also leads to Ugp1 phosphorylation 
(Grose et al., 2009). Therefore, it is possible that when glucose is limited, PASK 
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switches the utilization of the available glucose from storage to other more 
important cellular processes. 
 
1.1.3.2 PAS Kinase and Cell Growth 
In addition to its role in glucose partitioning, phosphorylation of Ugp1 by 
PASK is also involved in regulating cell growth. Yeast strains harboring a 
temperature-sensitive allele of Target of Rapamycin 2 (tor2ts) fail to grow at the 
restrictive temperature (37 °C) (Helliwell et al., 1994). This phenotype, however, 
can be suppressed by overexpression of yeast PASK (Cardon et al., 2012), or by 
treatment of cell wall perturbing agents (Bickle et al., 1998), which activate PASK. 
Interestingly, the rescue of tor2ts mutant requires Ugp1 phosphorylation as well 
as activation of Rho1, a small GTPase and a downstream effector of Tor2 in 
mediating temporal growth. Further studies showed that phosphorylated Ugp1 
nucleates the formation of a signaling complex at the cell membrane that 
includes Rom2, a Rho1 activating guanine nucleotide exchange factor, and Ssd1, 
a RNA binding protein. This complex activates Rho1 GTPase, which in turn 
stimulates the mitogen activated protein kinase (MAPK) signaling pathway and 
promotes cell growth and division (Helliwell et al., 1998). These observations 
suggest that yeast PASK can coordinate cell growth by phosphorylating Ugp1, 
which initiates a progrowth signaling cascade as well as increases the production 
of precursors for cell wall biogenesis. 
PASK may also control cell growth by regulating protein synthesis. A yeast 
proteomic screen for PASK substrates has identified several proteins that are 
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involved in protein translation, such as Cap-associated factor 20 (Caf20), the 
yeast homolog of mammalian 4E-BP, Tif11, the yeast eukaryotic translation 
initiation factor 1A (eIF1A), and Sro9, an mRNA-binding protein (Rutter et al., 
2002). All three proteins can be phosphorylated by PASK in vitro. However, the 
physiological relevance of these phosphorylation events awaits further 
investigation. In yeast, protein translation is strongly regulated by target of 
rapamycin complex 1 (TORC1) (Loewith et al., 2002). Interestingly, a recent 
study suggests that PASK may act as a negative regulator of TORC1 (DeMille et 
al., 2015). Under nutrient depleted conditions, Snf1 phosphorylates and activates 
PASK, which in turn leads to phosphorylation and activation of poly(A)-binding 
protein binding protein 1 (Pbp1), a component of stress granules. Active Pbp1 
then inhibits TOC1 by sequestering the complex at stress granules.  
 
1.1.4 PAS Kinase Function in Mammals 
The specific glucose partitioning function of PASK in yeast described 
above is not conserved in mammals. PASK phosphorylation site in yeast Ugp1 is 
not conserved in its human or mouse homolog, nor is human UGP1 
phosphorylated by human PASK in vitro (Hao and Rutter, 2008). Although 
differing in mechanism, mammalian PASK has been shown to participate in 










Figure 1-2. PAS kinase function in mammals. In pancreatic β-cells, PASK 
stimulates the expression of the insulin gene via PDX-1 transcription factor. 
PASK phosphorylates and inhibits GSK3β, thus promoting the protein stability of 
PDX-1. PASK also suppresses glucagon production in α-cells and regulates lipid 
metabolism in liver. Upstream signaling cues that mediate PASK activation 
remain largely elusive. Glucose stimulation in pancreatic β-cells has been shown 














































1.1.4.1 PAS Kinase and Insulin Production 
Studies using Min6 cells, a mouse pancreatic β-cell line, and isolated rat 
islets indicate that PASK plays a role in regulating insulin production. Incubation 
of cells with high glucose not only increased the expression of PASK, but also 
promoted its kinase activity (da Silva Xavier et al., 2004). Overexpression of wild-
type PASK stimulated, while kinase-inactive PASK inhibited, the transcription of 
the preproinsulin gene (hereafter referred to as the insulin gene) under basal and 
high glucose conditions, respectively. Inhibition of PASK, either by RNAi silencing 
or by microinjection of PASK antibody, also abolished glucose-stimulated 
transcription of the insulin gene. The effect of PASK on the insulin gene promoter 
is mediated by pancreatic duodenum homeobox-1 (PDX-1) transcription factor. 
PASK promotes the transcription of PDX-1 gene, as silencing of PASK or 
overexpression of kinase-inactive PASK decreased glucose-induced PDX-1 gene 
expression. In addition, PASK also promotes the stability of PDX-1 protein 
(Semache et al., 2013). Under low glucose condition, PDX-1 is phosphorylated 
by glycogen synthase kinase 3β (GSK3β), which triggers its proteasomal 
degradation (Humphrey et al., 2010). This process is inhibited under high glucose 
condition. A recent study showed that overexpression of wild-type PASK 
mimicked the effect of glucose stimulation on PDX-1 protein stability. PASK 
inhibited GSK3β by direct phosphorylation at serine-9 position, which in turn 
lowered PDX-1 phosphorylation level and prevented its degradation (Semache et 
al., 2013). Again, this effect was reversed by PASK silencing or overexpression 




Two SNPs, L1051V and G1117E, have been identified in the human 
PASK gene that are associated with maturity-onset diabetes of the young 
(MODY), a dominantly inherited form of early onset diabetes (Semplici et al., 
2011). The G1117E mutation increased PASK activity in vitro and enhanced 
basal insulin secretion when expressed in isolated mouse islets. These 
observations further support a positive role of PASK in regulating insulin 
production. 
 
1.1.4.2 PAS Kinase and Glucagon Production 
Another function of PASK in the pancreas is to regulate glucagon 
production (da Silva Xavier et al., 2011). The expression level of PASK is 
approximately two-fold higher in α-cells compared to that in β-cells. Whole-body 
PASK knockout (Pask-/-) mice showed increased fasting blood glucose and 
plasma glucagon level compared to wild-type mice. Consistent with that, islets 
isolated from Pask-/- mice secreted more glucagon and less insulin than in wild-
type islets. Further studies showed that PASK silencing in α-TC1-9 cells blocked 
glucose’s ability to suppress glucagon secretion, while PASK overexpression in 
the same cells, as well as in human islets, inhibited glucagon secretion. The 
regulation of glucagon production by PASK likely occurs at the level of 
transcription, and is potentially mediated by AMPK-α2. However, the detailed 
mechanism still requires further investigation. Interestingly, the same study 
showed that PASK expression was significantly decreased in islets from human 
type 2 diabetes (T2D) patients compared to healthy controls. This downregulation 
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of PASK may potentially lead to increased fasting and postprandial glucagon 
level, as well as decreased postprandial insulin level; all of which are associated 
with T2D and other metabolic diseases. 
 
1.1.4.3 Characterization of PAS Kinase Knockout Mice 
To further study the physiological function of mammalian PASK, our lab 
studied germline PASK knockout (Pask-/-) mice (Hao et al., 2007). Pask-/- mice 
are viable and fertile with no obvious developmental defects. Consistent with the 
results from cultured Min6 cells and islets, Pask-/- mice showed impaired insulin 
secretion in response to glucose stimulation. No changes in islet morphology or 
β-cell mass were observed upon PASK deficiency. When fed with a standard 
normal chow diet, Pask-/- mice exhibited no difference in metabolism compared to 
their wild-type littermates. Interestingly, when challenged with a high-fat diet 
(HFD), Pask-/- mice showed decreased susceptibility to diet-induced metabolic 
disorders. Unlike their wild-type littermates, PASK deficient mice gained less 
weight, showed improved insulin sensitivity and elevated metabolic rate. The 
most profound phenotype observed in these mice, however, was the nearly 
complete protection from HFD-induced triglyceride accumulation in liver (hepatic 
steatosis). This is also accompanied by decreased expression of genes involved 
in lipid metabolism, such as fatty acid transporter (Cd36), stearoyl-CoA 
desaturase 1 (Scd1) and peroxisome proliferator-activated receptor γ (Pparγ). 
These data suggest a potential role of PASK in regulating lipid metabolism in liver, 
and here, we show that PASK activates fatty acid and triglyceride synthesis 
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through sterol regulatory element binding protein 1 (SREBP-1), the master 
transcription factor that drives the lipogenic program in liver. 
 
1.2 Sterol Regulatory Element Binding Proteins (SREBPs) 
Sterol regulatory element binding proteins (SREBPs) are a family of 
transcription factors that belong to the basic-helix-loop-helix-leucine zipper 
(bHLH-LZ) transcription factor family (Brown and Goldstein, 1997). This family 
was first identified in 1993 by Michael Brown and Joseph Goldstein’s group as 
transcription factors for genes involved in lipid metabolism (Briggs et al., 1993; 
Wang et al., 1993). In mammals, there are three isoforms in this family. SREBP-
1a and SREBP-1c are produced from a single gene SREBF-1 using alternative 
promoters (Hua et al., 1995b). These two isoforms only differ in their respective 
first exons. SREBP-2 is encoded by a separate gene SREBF-2. SREBP-1a and 
SREBP-2 are ubiquitously expressed at a relatively constant level, while SREBP-
1c is the predominant isoform in metabolic tissues including liver and white 
adipose tissue (Shimomura et al., 1997; Ye and DeBose-Boyd, 2011). 
 
1.2.1 SREBP Domain Structure 
The domain organization of SREBPs reveals a unique feature of this 
transcription factor family. All SREBPs possess (1) a transcriptional activation 
domain (TAD) located at the extreme N-terminus of the protein, followed by a 
bHLH-LZ domain that mediates DNA binding and protein dimerization; (2) a 
middle segment that contains two membrane-spanning helices separated by a 
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short hydrophilic sequence; and (3) a C-terminal regulatory domain (Brown and 
Goldstein, 1997). The full-length SREBPs are membrane-bound proteins and 
require a proteolytic activation step, known as SREBP maturation, to release the 
transcriptionally active N-terminal portion of the transcriptions factors.  
 
1.2.2 SREBP Maturation 
All SREBPs are first synthesized as inactive precursor forms that are 
anchored on the endoplasmic reticulum (ER) membrane by the two 
transmembrane domains in a hairpin configuration: the N-terminal and C-terminal 
domains face the cytoplasmic side of the ER membrane, while the hydrophilic 
loop between the transmembrane domains projects into the ER lumen (Figure 1-
3) (Brown and Goldstein, 1997; Hua et al., 1995a). In order for the N-terminal 
transcriptionally active portion of SREBPs to enter the nucleus, the precursor 
SREBPs undergo a maturation process, during which the precursor forms 
translocate from the ER to the Golgi membrane where two proteolytic cleavage 
events release the N-terminal fragment of SREBPs (Brown and Goldstein, 2009; 
Ye and DeBose-Boyd, 2011). A number of ER and Golgi membrane proteins, 
including SCAP, Insig, S1P and S2P play critical roles in regulating and 
performing SREBP maturation. 
 
1.2.2.1 SREBP Cleavage Activating Protein (SCAP) 
SREBP cleavage activating protein (SCAP) is a polytopic ER membrane 





Figure 1-3. Regulation of SREBP activation. SREBPs are highly regulated at 
multiple levels in response to a wide range of intrinsic and extrinsic signals. 
Regulation occurs at the levels of transcription, posttranslational proteolytic 
maturation, transcriptional activity and also protein stability. Positive regulation is 
shown in green, whereas negative regulation is shown in red. ℗ indicates 










































terminal part of SCAP contains eight transmembrane helices, and the C-terminal 
cytosolic part contains a tryptophan-aspartate-repeat (WD) domain that interacts 
with the C-terminal regulatory domains of SREBPs. SCAP escorts the 
translocation of SREBPs from the ER to the Golgi by interacting with the 
Sec23/24 subunit of the coat protein complex II (COPII) trafficking machinery, 
thus allowing the SCAP/SREBP complex to be exported from the ER via COPII-
coated vesicles (Espenshade et al., 2002; Nohturfft et al., 2000). The interaction 
between SCAP and the Sec23/24 subunit is mediated through the core sequence 
MELADL within the cytosolic loop 6 (between transmembrane helices 6 and 7) of 
the SCAP protein. Once SREBPs undergo proteolysis on the Golgi membrane, 
SCAP is released and recycled back to the ER (Sun et al., 2005; Sun et al., 
2007). SCAP is required for SREBP maturation (Sakai et al., 1998a). Liver-
specific disruption of the Scap gene significantly lowered the levels of the mature 
SREBPs, decreased expression of their lipogenic target genes and also reduced 
lipid synthesis in liver (Matsuda et al., 2001; Moon et al., 2012). 
 
1.2.2.2 Insulin-Induced Genes (Insigs) 
Insulin induced genes (Insigs) are a family of ER membrane resident 
proteins (Dong and Tang, 2010). There are two isoforms in mammalian cells, 
designated as Insig1 and Insig2. Insig1 was first identified in regenerating rat liver 
(Peng et al., 1997), and its expression is induced by insulin treatment (Diamond 
et al., 1993). Rodent Insig2 gene encodes two transcript variants, Insig2a and 
Insig2b, using alternative promoters with noncoding first exons (Yabe et al., 2002; 
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Yabe et al., 2003). Insig2b is constitutively expressed in most tissues, while 
Insig2a is the predominant form in liver (Yabe et al., 2003). Although the 5’ 
untranslated region (5’ UTR) is different between Insig2a and Insig2b, they both 
are translated into the same protein product, Insig2. In human, INSIG1 (277 
amino acids) and INSIG2 (225 amino acids) proteins are 59% identical in amino 
acid sequence (Yabe et al., 2002; Yang et al., 2002). Both isoforms contain six 
transmembrane helices (Feramisco et al., 2004; Goldstein et al., 2006). Insig 
proteins negatively regulate SREBP maturation by interacting with SCAP and 
retaining the SCAP/SREBP complex on the ER membrane (Adams et al., 2004; 
Yang et al., 2002). Deletion of both Insig isoforms in mouse liver resulted in 
accumulation of mature SREBPs, increased expression of their lipogenic target 
genes and elevated rate of lipid synthesis (Engelking et al., 2005). 
Overexpression of human INSIG1 in mouse liver, on the other hand, caused the 
opposite effects on SREBP maturation and lipogenesis (Engelking et al., 2004). 
 
1.2.2.3 Site-1 Protease (S1P) and Site-2 Protease (S2P) 
Once transported to the Golgi, SREBPs undergo two sequential proteolytic 
cleavage events to liberate the N-terminal part of the protein (Sakai et al., 1996). 
The first cleavage occurs at a conserved leucine residue (RXXL/) within the 
luminal loop between the two transmembrane helices (Duncan et al., 1997; Sakai 
et al., 1998b). This step divides SREBPs into two halves, each still embedded in 
the membrane by a single transmembrane helix. This first proteolytic cleavage is 
mediated by site-1 protease (S1P), a membrane-bound serine protease with a 
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luminal catalytic domain (Rawson et al., 1998; Sakai et al., 1998b). The second 
cleavage occurs within the first transmembrane helix of SREBPs, which liberates 
the N-terminal fragment of SREBPs (Duncan et al., 1998). This proteolysis step 
is mediated by site-2 protease (S2P), a membrane-bound hydrophobic zinc 
metalloprotease whose active site (HEXXH) is embedded within the membrane 
(Rawson et al., 1997; Zelenski et al., 1999). S1P or S2P deficient cells are 
auxotrophic for cholesterol, indicating their essential roles in generating 
transcriptionally active form of SREBPs (Rawson et al., 1998; Sakai et al., 1996). 
Indeed, liver-specific disruption of the S1p gene led to significant decrease in 
mature SREPBs levels, lipogenic gene expression, as well as lipid production 
(Yang et al., 2001). 
The N-terminal fragments of SREBPs, also known as the mature forms, 
contain a nuclear localization signal that facilitates their translocation into the 
nucleus to activate the transcription of their target genes (Nagoshi and Yoneda, 
2001).  
 
1.2.3 Transcription Activation by SREBPs 
After proteolytic maturation, the mature forms of SREBPs drive 
transcription of their target genes by binding to specific sequence motifs within 
the promoters of their targets. Unlike other bHLH-LZ family transcription factors, 
which typically bind to a palindromic E-box DNA motif (5’-CANNTG-3’) (Murre et 
al., 1994), the mature SREBPs can also bind to a 10-base-pair (bp) motif called 
sterol regulatory element (SRE) (5’-ATCACCCCAC-3’) (Kim et al., 1995; Smith et 
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al., 1990). This is because SREBPs have a tyrosine residue in their DNA binding 
basic domains instead of an arginine that is found in all other bHLH-LZ 
transcription factors (Kim et al., 1995). Structural studies suggest that the 
tyrosine residue causes a conformational change in the basic domains, which 
allows SREBPs to bind to the SRE with high affinity (Parraga et al., 1998). 
In addition to recognizing SREs in the promoter regions of the target 
genes, the mature forms of SREBPs also recruit non-DNA-binding transcription 
coactivators through their N-terminal TADs to further facilitate transcriptional 
activation (Osborne and Espenshade, 2009; Sato et al., 1994). Both SREBP-1a 
and SREBP-2 have longer TADs that contain conserved residues required for 
their interaction with transcription coactivators, such as CBP/p300, a histone 
acetyltransferase, and Mediator, a multi-subunit complex essential for RNA 
polymerase II mediated transcription (Oliner et al., 1996; Toth et al., 2004; Yang 
et al., 2006). These residues are not present in the shorter SREBP-1c TAD due 
to the alternative first exon (Toth et al., 2004). As a result, SREBP-1c interacts 
with CBP/p300 and Mediator with much lower affinity, thus attenuating its 
transactivation potential. 
 
1.2.4 Function of SREBPs 
All SREBPs regulate lipid synthesis with distinct and overlapping functions. 
SREBP-1c primarily stimulates the transcription of genes involved in fatty acid 
and triglyceride biosynthesis, while SREBP-2 mainly drives the transcription of 
genes involved in cholesterol biosynthesis (Horton et al., 2002; Pai et al., 1998). 
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SREBP-1a can activate genes in both biosynthesis pathways. Various mouse 
models have been made to manipulate SREBPs levels. Germline SREBP-1 
knockout mice, which lack both SREBP-1a and SREBP-1c, are partially 
embryonic lethal (Shimano et al., 1997b). The surviving knockout mice showed 
increased expression of SREBP-2 and its target genes, as well as elevated 
cholesterol synthesis in liver. Germline SREBP-2 knockout mice, on the other 
hand, are completely embryonic lethal. These results indicate that SREBP-2 can 
compensate for the loss of SREBP-1, while SREBP-2 itself is an essential gene. 
Disruption of SREBP-1c alone does not lead to embryonic lethality (Liang et al., 
2002). Mice lacking SREBP-1c showed decreased hepatic expression of 
enzymes involved in fatty acid biosynthesis, reduced fatty acid synthesis and 
increased cholesterol synthesis caused by SREBP-2 compensation. 
Transgenic mice have also been generated to specifically express the 
mature form of each SREBP isoform in the liver. Hepatic overexpression of 
mature SREBP-1a greatly promoted the expression of genes involved in the fatty 
acid, triglyceride and cholesterol biosynthesis pathways (Shimano et al., 1996). 
This was accompanied by a 20-fold increase in fatty acid and triglyceride 
synthesis and a five-fold increase in cholesterol synthesis. Overexpression of 
mature SREBP-1c in liver, on the other hand, only induced triglyceride 
accumulation by five-fold (Shimano et al., 1997a), consistent with it being a 
weaker transcription factor. Interestingly, no changes in cholesterol level were 
observed in these animals. In contrast to SREBP-1, hepatic overexpression of 
SREBP-2 favored cholesterol biosynthesis, resulting in a 20-fold increase in 
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cholesterol level and a four-fold increase in triglyceride level in liver (Horton et al., 
1998). 
Recent studies have shown that SREBPs target genes are not limited to 
lipogenic enzymes or confined to liver. For example, in macrophages, SREBP-1a 
facilitates the pro-inflammatory response by activating the expression of Nlrp1a, 
a subunit of the inflammasome that mediates the activation of pro-inflammatory 
cytokines (Im et al., 2011). Additionally, a genome-wide ChIP-sequencing study 
revealed that SREBP-2 occupies the promoter regions of genes involved in 
autophagy, implicating the involvement of SREBP-2 in the regulation of genes 
governing autophagy (Seo et al., 2011). 
  
1.2.5 Regulation of SREBPs 
As the master transcriptional regulators of lipogenesis in mammalian cells, 
SREBPs are tightly regulated at multiple levels in response to a variety of 
extracellular and intracellular signals. This allows cells to coordinate their 
metabolic status with changes in the cellular environment. Here, we discuss the 
effects of various signals on SREBP gene transcription, proteolytic maturation, 
transcriptional activity and protein stability (Figure 1-3). 
 
1.2.5.1 Regulation of SREBPs by Sterol 
Studies have demonstrated that maturation of SREBP-1a and SREBP-2 is 
subjected to feedback inhibition by sterol (Figure 1-3). Under sterol-depleted 
conditions, the SCAP/SREBP complex migrates to the Golgi via COPII-coated 
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vesicles (Espenshade et al., 2002; Nohturfft et al., 2000; Sun et al., 2005). 
Mature SREBPs are released from the Golgi membrane and in turn enter the 
nucleus to activate genes involved in cholesterol biosynthesis. When intracellular 
sterol levels are restored, cholesterol directly binds to the sterol-sensing domain 
of SCAP (transmembrane helices 2-5) (Radhakrishnan et al., 2004), which 
triggers a conformational change in the cytosolic loop 6 that contains the binding 
site for the Sec23/24 subunit of the COPII trafficking machinery (Brown et al., 
2002; Sun et al., 2005). This conformational change triggers the association of 
SCAP with Insig proteins, which disrupts its interaction with the Sec23/24 subunit. 
Cholesterol derivatives oxysterols also promote SCAP-Insig interaction by 
directly binding to Insig proteins (Radhakrishnan et al., 2007). As a result, the 
SCAP/SREBP complex is retained in the ER, which leads to a decreased rate of 
cholesterol synthesis. 
Insig1 also plays a role in the feedback inhibition of SREBP maturation. 
Upon sterol depletion, Insig1 dissociates from SCAP and becomes susceptible to 
ubiquitination and proteasomal degradation (Gong et al., 2006). This process is 
mediated by glycoprotein 78 (gp78), a membrane-bound E3 ubiquitin ligase (Lee 
et al., 2006b). Under sterol-repleted conditions, SCAP binds to Insig1, which 
precludes its interaction with gp78, thus leading to Insig1 stabilization. 
Interestingly, Insig1 itself is an SREBP target gene (Yabe et al., 2002). Therefore, 
activation of SREBPs not only elevates sterol level, but also promotes Insig1 
protein accumulation on the ER membrane, both of which inhibit further activation 
of SREBPs in a convergent manner. Unlike Insig1, Insig2 protein has a much 
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lower turnover rate that is not affected by sterol (Lee et al., 2006a). Insig2 
expression is not activated by SREBPs, either (Yabe et al., 2002). The role of 
Insig2 in regulating SREBP maturation will be discussed below. 
In addition to SREBP maturation, oxysterols can also activate SREBP-1c 
transcription and fatty acid synthesis. Oxysterols serve as agonists of nuclear 
receptor liver X receptor (LXR) and promote its binding to the SREBP-1c 
promoter (DeBose-Boyd et al., 2001; Repa et al., 2000; Yoshikawa et al., 2001). 
It is proposed that under sterol-replete conditions, cells increase fatty acid 
synthesis to promote cholesterol esterification. 
 
1.2.5.2 Regulation of SREBPs by Insulin Signaling 
Insulin is a hormone that is secreted by pancreatic β-cells in response to 
elevated levels of blood glucose and other nutrients following food intake 
(Samuel and Shulman, 2012). It acts on metabolic tissues to promote nutrient 
absorption and storage for future use. In muscle, insulin stimulates glucose 
uptake and glycogen synthesis. In white adipose tissue, insulin also promotes 
glucose uptake and lipid synthesis while suppressing lipolysis. In liver, insulin 
inhibits glucose production via gluconeogenesis and at the same time activates 
glycogen synthesis and lipogenesis. All these actions are carried out by an 






1.2.5.2.1 Insulin Signaling Pathway in the Liver 
The insulin signaling pathway in liver is initiated by binding of insulin to the 
insulin receptor (IR) tyrosine kinase, which triggers its dimerization and auto-
phosphorylation (Saltiel and Kahn, 2001). Activated IR recruits and 
phosphorylates insulin receptor substrates 1/2 (IRS1/2) on tyrosine residues, 
which then serve as binding sites for phosphatidylinositol-3-OH kinase (PI3K), 
leading to its activation. PI3K is a lipid kinase that phosphorylates 
phosphoinositide-4,5-phosphate (PIP2) at 3’-OH position to generate 
phosphoinositide-3,4,5-phosphate (PIP3) on the plasma membrane. PIP3 is then 
recognized by the pleckstrin homology (PH) domains of 3-phosphoinositide 
dependent kinase 1 (PDK1) and protein kinase B (PKB)/Akt, which leads to the 
membrane translocation of these two kinases and the subsequent 
phosphorylation of Akt by PDK1 at threonine residue 308. In addition to PDK1 
phosphorylation, Akt is also phosphorylated by the mechanistic target of 
rapamycin (mTOR) complex 2 (mTORC2) at serine residue 473 (Vadlakonda et 
al., 2013). Both phosphorylation events are required for the full activation of Akt. 
Once activated, Akt phosphorylates a wide range of downstream targets to 
modulate cell metabolism and other functions.  
1.2.5.2.1.1 Insulin and hepatic glucose metabolism.  Insulin regulates 
hepatic glucose metabolism through two mechanisms, both mediated by Akt 
(Saltiel and Kahn, 2001). First, insulin inhibits gluconeogenesis to prevent further 
elevation of blood glucose concentration. Akt phosphorylates the transcription 
factor Forkhead box protein 1 (FoxO1), resulting in its nuclear exclusion and the 
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downregulation of its gluconeogenic target genes. Second, insulin stimulates 
glycogen synthesis to promote glucose storage. Akt phosphorylates and inhibits 
glycogen synthase kinase 3 (GSK3), which in turn leads to the activation of 
glycogen synthase (GS) and increased glycogen synthesis.  
1.2.5.2.1.2 Insulin and hepatic lipid metabolism.  Insulin promotes the 
conversion of dietary carbohydrates (de novo lipogenesis) and fatty acids (fatty 
acid esterification) into triglyceride in liver, which is then transported to white 
adipose tissue for long-term storage (Krycer et al., 2010; Saltiel and Kahn, 2001). 
SREBP-1c is the major transcriptional regulator of fatty acid and triglyceride 
synthesis in liver in response to insulin signaling. Growing evidence indicates that 
insulin activates SREBPs at multiple levels, including gene transcription, 
proteolytic maturation, transcriptional activity and protein stability. 
 
1.2.5.2.2 Effect of Insulin Signaling on SREBP Transcription 
Insulin selectively regulates the transcription of SREBP-1c (Osborne and 
Espenshade, 2009; Zhang et al., 2005). The mRNA level of SREBP-1c in mouse 
and rat liver was reduced under fasted conditions and was robustly induced upon 
feeding, which stimulates the release of insulin (Horton et al., 1998; Li et al., 
2010). Rats treated with streptozotocin, a chemical that causes pancreatic β-cell 
failure and insulin deficiency, showed a profound decrease in hepatic SREBP-1c 
mRNA level (Shimomura et al., 1999b). This decrease was completely reversed 
by administration of insulin. The effect of insulin on SREBP-1c transcription can 
also be recapitulated in isolated rat primary hepatocytes (Chen et al., 2004; Li et 
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al., 2010). These results indicate that insulin is a potent activator of SREBP-1c 
transcription. 
Early studies demonstrated that the LXR nuclear receptor is required for 
SREBP-1c transcriptional activation by insulin (Figure 1-3). Mutating the LXR 
binding elements (LXRE) in the SREBP-1c promoter abolished its ability to 
respond to insulin stimulation (Chen et al., 2004). The mechanism of how insulin 
activates LXR remains unclear. In addition, SREBP-1c can also activate its own 
transcription by binding to the SRE motif in its own promoter (Amemiya-Kudo et 
al., 2000), thus establishing a feed-forward transcriptional regulatory loop upon 
insulin stimulation. 
Recent studies have shown that insulin-stimulated SREBP-1c transcription 
depends on PI3K, Akt and mTOR complex 1 (mTORC1) (Figure 1-3) (Li et al., 
2010).  mTORC1 is a major downstream effector of Akt (Sarbassov et al., 2005). 
Upon insulin stimulation, Akt directly phosphorylates and inactivates tuberous 
sclerosis 2 (TSC2) within the TSC1-TSC2 complex. TSC2 is a GTPase activating 
protein (GAP) for Ras homolog enriched in brain (Rheb) small GTPase. 
Phosphorylation of TSC2 by Akt causes an increase in GTP-bound Rheb, which 
in turn leads to mTORC1 activation. In rat primary hepatocytes, insulin-induced 
transcriptional activation of SREBP-1c was blocked by small molecule inhibitors 
of PI3K (wortmannin), Akt (Akti-1/2) and mTORC1 (rapamycin) (Li et al., 2010), 
indicating that mTORC1 plays an essential role in activating SREBP-1c 
transcription upon insulin stimulation. Interestingly, pharmacological inhibition of 
p70 ribosomal S6 kinase (S6K), a kinase directly activated by mTORC1, had no 
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effect on SREBP-1c transcription, suggesting an alternative downstream effector 
of mTORC1 in this regulatory process. 
 
1.2.5.2.3 Effect of Insulin Signaling on SREBP Maturation 
In addition to transcription, insulin also stimulates SREBP-1c maturation. 
In rat primary hepatocytes, insulin treatment rapidly increased the abundance of 
mature SREBP-1 without affecting the levels of SREBP-1 mRNA or the precursor 
form (Hegarty et al., 2005). A similar effect was also observed in rat liver with 
constitutive expression of human SREBP-1c (Owen et al., 2012), indicating that 
insulin can specifically activate SREBP-1c maturation. 
Similar to transcriptional activation, proteolytic activation of SREBP-1c by 
insulin also requires PI3K, Akt and mTORC1 (Figure 1-3). Pharmacological 
inhibition and siRNA knockdown of these three components in the insulin 
signaling pathway both led to decreased SREBP-1c maturation (Owen et al., 
2012; Porstmann et al., 2008), indicating their essential roles in regulating this 
process. Whether S6K regulates SREBP-1 maturation downstream of mTORC1 
is still under debate. An S6K inhibitor decreased SREBP-1c maturation in rat 
primary hepatocytes upon insulin stimulation (Owen et al., 2012). A similar effect 
was observed in TSC1 null mouse embryonic fibroblasts (MEFs), where siRNA 
knockdown of S6K suppressed SREBP-1 maturation induced by mTORC1 
hyperactivation (Duvel et al., 2010). However, in a separate study, S6K silencing 
showed no effect on SREBP-1 maturation following Akt activation in wild-type 
MEFs or in human retinal pigment epithelial cells (Lewis et al., 2011). These 
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results raise the possibility of an alternative downstream effector of mTORC1 in 
mediating SREBP-1 maturation. 
Insulin also activates SREBP-1 maturation by suppressing Insig2a (Figure 
1-3) (Yabe et al., 2003). Insig2a is the major Insig isoform in liver (Yabe et al., 
2003), and Insig2 protein preferentially interacts with the SCAP-SREBP-1c 
complex (Yellaturu et al., 2009b), causing its ER retention. Upon insulin 
stimulation, Akt promotes the degradation of Insig2a mRNA via its 3’ UTR 
(Yellaturu et al., 2009b), but the detailed mechanism remains unknown. 
Suppression of Insig2a mRNA levels by insulin is not mediated by mTORC1, as 
rapamycin has no effect on the Insig2a mRNA level (Yecies et al., 2011). 
Therefore, insulin regulates SREBP-1c maturation via two distinct pathways 
downstream of Akt: one that depends on mTORC1 activation and one that 
involves Insig2a degradation. Both pathways are required for activation of 
SREBP-1c maturation, as demonstrated by the observations from Tsc1 liver-
specific knockout mice (Yecies et al., 2011). Despite hyperactivation of mTORC1 
in liver, these mice showed a significant decrease in SREBP-1c target gene 
expression and failed to develop hepatic steatosis when fed with a HFD. Further 
studies demonstrated that constitutive activation of mTORC1 resulted in 
feedback inhibition of insulin/PI3K/Akt signaling, which in turn led to accumulation 
of Insig2a and suppression of SREBP-1c maturation. 
It has been reported that insulin can also stimulate SREBP-1c maturation 
by promoting its phosphorylation (Figure 1-3). In rat primary hepatocytes, insulin 
treatment led to increased serine and threonine phosphorylation of SREBP-1c in 
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an Akt-dependent manner, which increased the affinity of SCAP-SREBP-1c 
complex for the Sec23/24 subunit of the COPII vesicles (Yellaturu et al., 2009a). 
The kinase that mediates this phosphorylation event, as well as the connection 
between SREBP-1c phosphorylation and mTORC1 activation, awaits further 
investigation.  
 
1.2.5.2.4 Effect of Insulin Signaling on Mature SREBPs 
The mature forms of SREBPs are highly unstable and are susceptible to 
ubiquitination and proteasomal degradation (Hirano et al., 2001; Wang et al., 
1994). This process depends on the transcriptional activity of SREBPs, as 
mutations in the TAD or DNA-binding domains of SREBPs stabilize the proteins 
(Sundqvist and Ericsson, 2003). Upon binding to DNA, SREBP-1a/c recruits 
GSK3, which phosphorylates SREBP-1a at threonine residue 426 (threonine 402 
in SREBP-1c) and serine residue 430 (serine residue 406 in SREBP-1c) (Figure 
1-3) (Kim et al., 2004; Punga et al., 2006; Sundqvist et al., 2005). 
Phosphorylation on these two residues creates a docking site for F-box and WD 
repeat domain-containing 7 (Fbw7) E3 ubiquitin ligase, which in turn promotes 
ubiquitination and proteasomal degradation of SREBP-1 (Sundqvist et al., 2005). 
Upon insulin stimulation, Akt phosphorylates GSK3 at serine residue 9 and 
inhibits its activity (Cross et al., 1995). As a result, Fbw7 can no longer recognize 
SREBP-1, thus preventing SREBP-1 from degradation.  
A recent study revealed that, in addition to transcriptional and proteolytic 
activation of SREBPs, mTORC1 also promotes the nuclear abundance of mature 
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SREBPs. This effect is mediated by lipin 1, a phosphatidic acid phosphatase 
(Figure 1-3) (Peterson et al., 2011). mTORC1 directly phosphorylates lipin 1 at 
multiple sites. This phosphorylation prevents its entry into nucleus, which in turn 
leads to accumulation of nuclear SREBPs. Genetic and pharmacological 
inhibition of mTORC1 causes lipin 1 nuclear translocation, decreased SREBP 
nuclear abundance and redistribution of SREBPs to the periphery of nucleus. 
The same results were also observed using a mutant form of lipin 1 that lacks all 
mTORC1 phosphorylation sites. Interestingly, SREBPs can activate transcription 
of the gene encoding lipin 1 (Ishimoto et al., 2009), suggesting negative feedback 
regulation. Future studies will need to be done to elucidate the mechanism 
whereby lipin 1 regulates the abundance and the localization of mature SREBPs 
in the nucleus. 
 
1.2.5.3 Regulation of SREBPs by ER Stress 
The ER is a membranous organelle that plays a crucial role in protein 
synthesis and folding, transport, trafficking and lipid synthesis (Hotamisligil and 
Erbay, 2008; Ron and Walter, 2007). ER stress is a result of accumulation of 
unfolded or misfolded proteins in the ER lumen, which can be caused by 
elevated protein synthesis, calcium imbalance, nutrient overload or other stimuli 
that disturb ER homeostasis. ER stress triggers an adaptive response called the 
unfolded protein response (UPR). The UPR is mediated by three ER membrane 
proteins, pancreatic ER kinase (PERK), inositol-requiring kinase 1 (IRE1) and 
activating transcription factor 6 (ATF6). Under normal conditions, PERK, IRE1 
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and ATF6 are bound by an ER luminal chaperon glucose-regulated protein 78 
(Grp78) and remain inactive. Upon ER stress, accumulation of misfolded proteins 
overwhelms Grp78’s ability to neutralize and shield the exposed hydrophobic 
stretches of misfolded proteins.  As a result, Grp78 dissociates from PERK, IRE1, 
and ATF6, leading to their activation. Once activated, these three proteins 
cooperatively inhibit general protein translation while promoting the expression of 
ER chaperone proteins and protein degradation machinery to help restore ER 
homeostasis. In addition, membrane expansion also occurs during ER stress to 
increase its protein folding capacity. 
Studies have shown that ER stress activates SREBP maturation 
potentially to increase the synthesis of lipids needed for ER expansion (Figure 1-
3) (Lee and Ye, 2004; Werstuck et al., 2001). Two mechanisms have been 
proposed for this process. ER stress causes depletion of Insig1 protein due to 
inhibition of protein synthesis, as well as the high turnover rate of Insig1 itself 
(Bobrovnikova-Marjon et al., 2008; Lee and Ye, 2004). This in turn promotes 
SREBP maturation, which can be reversed by overexpression of Insig1 (Lee and 
Ye, 2004). Additionally, Grp78 may also play a role in regulating ER stress-
induced SREBP maturation. Overexpression of Grp78 in rat primary hepatocytes 
suppressed SREBP-1 maturation under ER stress conditions (Kammoun et al., 
2009). Moreover, Grp78 co-immunoprecipetated with SREBP-1 in the liver of 
lean mice but not obese mice. These results suggest a model where, similar to 
PERK, IRE1, and ATF6, Grp78 binds to SREBPs and prevents them from 
activation. Under ER stress conditions, Grp78 dissociates from SREBPs, which 
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allows the ER to Golgi transport and proteolytic activation of SREBPs. 
 
1.2.5.4 Regulation of SREBPs by Fatty Acids 
Similar to the feedback inhibition of SREBP-2 by sterol, SREBP-1 is 
subjected to feedback inhibition by fatty acids. This effect is mainly mediated by 
unsaturated fatty acids (UFA) at both transcriptional and posttranslational levels 
(Figure 1-3). UFA inhibits SREBP-1c transcription by antagonizing the LXR 
nuclear receptor (Ou et al., 2001). In mouse, only SREBP-1c transcription is 
regulated by UFA since the SREBP-1a promoter does not contain an LXRE 
(Repa et al., 2000; Zhang et al., 2005). In human, however, an LXRE is present 
in the promoters of both SREBP-1a and SREBP-1c (Ye and DeBose-Boyd, 2011). 
Therefore, UFA can inhibit the transcription of both SREBP-1 isoforms in human 
(Hannah et al., 2001). 
UFA also inhibits the maturation of SREBP-1 without affecting SREBP-2 
(Hannah et al., 2001). The exact mechanism underlying this effect is currently 
unknown, but it is proposed that Insig1 may potentially mediate this process. UFA 
stabilizes Insig1 protein by inhibiting its interaction with UBX domain-containing 
protein 8 (Ubxd8) (Lee et al., 2008). Ubxd8 recruits p97, an AAA-ATPase that 
extracts polyubiquitinated proteins from membrane for proteasomal degradation. 
The binding of Ubxd8/p97 to Insig1 is independent of sterol-induced Insig1 
ubiquitination, as this interaction neither requires nor blocks Insig1 ubiquitination 
(Ikeda et al., 2009; Lee et al., 2008). Both ubiquitination and recruitment of p97 
are required for the proteasomal degradation of Insig1 (Ikeda et al., 2009). Unlike 
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Insig1, UFA has no effect on Insig2 protein stability (Lee et al., 2008). Since 
Insig1 also regulates SREBP-2 maturation, how UFA specifically inhibits SREBP-
1 maturation through Insig1 will need to be addressed in future studies.  
 
1.2.5.5 Regulation of SREBPs by Glucagon 
When blood glucose level falls, α-cells in pancreas secrete glucagon to 
raise the glucose level in the bloodstream (Quesada et al., 2008). Glucagon 
binds to the glucagon receptor, a G protein-coupled receptor, which in turn 
activates adenylate cyclase. Adenylate cyclase produces cyclic AMP (cAMP), 
which can bind to the regulatory subunit of protein kinase A (PKA) to relieve its 
inhibition of the catalytic subunit. Once activated in the liver, PKA inhibits 
glycolysis and glycogen synthesis, while stimulating glycogenolysis and 
gluconeogenesis. PKA also suppresses lipid synthesis partially through SREBP-1 
inhibition (Figure 1-3). PKA directly phosphorylates LXR, which disrupts its 
dimerization with RXR and DNA binding, thus leading to decreased SREBP-1c 
transcription (Yamamoto et al., 2007). PKA can also phosphorylate mature 
SREBP-1 at serine residue 338 (1a) or 314 (1c), which attenuates SREBP-1 
transactivation and subsequently inhibits lipogenesis (Lu and Shyy, 2006). 
 
1.2.5.6 Regulation of SREBPs by AMPK 
AMP-activated protein kinase (AMPK) is a master regulator of cellular 
energy homeostasis (Kahn et al., 2005). It senses intracellular energy level by 
detecting changes in the AMP:ATP ratio. AMPK is activated in response to 
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increased AMP level in a low energy state. Upon activation, AMPK inhibits 
energy-consuming anabolic pathways and activates energy-producing catabolic 
pathways to increase the cellular ATP level. In liver, AMPK suppresses 
lipogenesis by phosphorylating and inhibiting acetyl-CoA carboxylase (ACC) and 
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), two rate-limiting enzymes 
in fatty acid and cholesterol biosynthesis pathways, respectively. Moreover, a 
recent study indicates that AMPK also inhibits SREBP maturation (Figure 1-3). 
AMPK directly phosphorylates SREBP-1c at serine residue 372, which in turn 
leads to a decreased level of the mature form and accumulation of the precursor 
form of SREBP-1c (Li et al., 2011). Serine to alanine mutation of the 
phosphorylation site abolishes the inhibitory effect of AMPK on SREBP-1c 
maturation. SREBP-2 is also a direct substrate of AMPK, but the phosphorylation 
site has not been identified. How phosphorylation on SREBPs by AMPK blocks 
the maturation process awaits further study. 
In addition to direct inhibition, AMPK can also indirectly affect SREBP 
activity through crosstalk with other nutrient sensors. For example, AMPK inhibits 
mTORC1 activity (Kahn et al., 2005), which in turn leads to the suppression of 
SREBPs. Additionally, AMPK may promote the degradation of mature SREBPs 
by enhancing the activity of Sirtuin 1 (SIRT1), an NAD+-dependent deacetylase 
(Ruderman et al., 2010; Walker et al., 2010). Mature SREBPs can be acetylated 
by their transcriptional coactivator CBP/p300 histone acetyltransferase 
(Giandomenico et al., 2003). This acetylation protects SREBPs from 
ubiquitination and proteasomal degradation. SIRT1 directly deacetylates mature 
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SREBPs, resulting in increased SREBP protein turnover and decreased lipid 
synthesis (Figure 1-3) (Walker et al., 2010). 
 
1.2.5.7 Additional Signals Regulating SREBPs 
Promoter analysis has provided insights into the transcriptional regulation 
of SREBP-1a and SREBP-2. SREBP-1a has a simple promoter containing an 
NF-κB-binding site flanked by two Sp1-binding sites (Zhang et al., 2005). NF-κB 
is a key transcription factor complex that mediates the expression of genes 
involved in immune response (Hayden and Ghosh, 2012). Consistent with this, it 
has been shown that in macrophages, lipopolysaccharide (LPS) challenge 
promotes the recruitment of NF-κB, as well as Sp1, to the SREBP-1a promoter. 
This leads to the transcriptional activation of SREBP-1a, which in turn promotes 
the expression of pro-inflammatory genes and lipogenesis (Im et al., 2011). The 
SREBP-2 promoter contains an SRE, and hence is subjected to feedforward 
autoregulation (Sato et al., 1996). In addition, the SREBP-2 promoter also 
contains a binding site for thyroid hormone receptor (TR), and is activated by TR 
in a ligand-dependent manner (Shin and Osborne, 2003). This is consistent with 
the decreased expression of SREBP-2 target gene LDL receptor (LDLR) in mice 
depleted with thyroid hormone (Ness et al., 1990). 
Intriguingly, a recent study suggests that SREBP maturation can occur in 
the absence of ER to Golgi transport. In this study, the authors found that 
SREBP-1 plays an essential role in promoting phosphatidylcholine (PC) 
biosynthesis (Walker et al., 2011). Decreased PC production stimulated SREBP-
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1 maturation. Interestingly, instead of affecting the ER exit of SREBP-1, low PC 
levels actually caused S1P and S2P to translocate from the Golgi to the ER 
membrane and cleave off the N-terminal mature form of SREBP-1. SREBP-2 
maturation was not affected by the PC level. The mechanism underlying the 
differential regulation of SREBP-1 and SREBP-2 will need to be addressed in 
future studies. 
The protein stability of mature SREBP-1c is also negatively regulated by 
cyclin-dependent kinase 8 (CDK8), a component of the Mediator complex. CDK8 
phosphorylates SREBP-1c at threonine residue 402, a site shared by GSK3, and 
promotes its degradation (Figure 1-3) (Zhao et al., 2012). Interestingly, CDK8 
expression is downregulated in response to insulin treatment in rat primary 
hepatocytes or feeding in mouse liver, consistent with its role as a suppressor of 
SREBP-1c. 
 
1.2.6 SREBPs and Metabolic Diseases 
The abundant supply of food high in calories and the relatively sedentary 
lifestyle in modern society has greatly accelerated the development and 
prevalence of metabolic diseases, including diabetes, obesity and nonalcoholic 
fatty liver disease (NAFLD). Metabolic diseases have become a major health 
concern in the United States. According to the CDC, over 29 million people 
nationwide have diabetes, and the estimated rates for adult and pediatric obesity 
have increased to 20-30% of the US population (Browning et al., 2004). NAFLD 
is another major form of metabolic disease, affecting over 30% of the general 
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population in the US (World Gastroenterology Organisation, 2012). NAFLD is 
strongly associated with diabetes and obesity. Over 90% of the obese patients 
with T2D are also diagnosed with NAFLD (Tolman et al., 2007). As discussed 
below, NAFLD greatly contributes to the disease phenotype of T2D. In addition, 
individuals with NAFLD have higher risk of progression towards more serious 
liver diseases, such as nonalcoholic steatohepatitis (NASH), cirrhosis, 
hepatocellular carcinoma and liver failure (Cohen et al., 2011). 
The hallmark of NAFLD is the excessive accumulation of triglyceride in 
hepatocytes (hepatic steatosis) (Cohen et al., 2011). As the master regulator of 
fatty acid and triglyceride biosynthesis, SREBP-1 plays a crucial role in the 
development of hepatic steatosis. Overexpression of mature SREBP-1a and 
SREBP-1c in mouse liver increased the hepatic TAG level by 20 fold and five fold, 
respectively (Shimano et al., 1996; Shimano et al., 1997a). On the other hand, 
deletion of SREBP-1 attenuated fatty liver in leptin-deficient Ob/Ob mice, a 
genetic model of obesity (Yahagi et al., 2002). Moreover, the hepatic protein 
abundance of mature SREBP-1 was significantly elevated in Ob/Ob mice as well 
as in HFD-fed wild-type mice (Leavens et al., 2009; Shimomura et al., 1999a). 
This was associated with increased expression of SREBP-1 target genes and 
fatty acid synthesis. These results indicate that hyperactivation of SREBP-1 plays 
a causal role in the onset of hepatic steatosis. 
The main characteristic of these metabolic diseases is insulin resistance. It 
is a condition where the body does not respond to insulin action efficiently due to 
impaired insulin signaling (Samuel and Shulman, 2012). For example, in liver, 
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insulin fails to activate glycogen synthesis and suppress gluconeogenesis under 
insulin resistant conditions, resulting in hyperglycemia. Hyperglycemia leads to 
hyperinsuliemia, as insulin secretion from pancreatic β-cells accelerates to 
compensate for the elevated blood glucose level. Interestingly, however, SREBP-
1c-mediated lipogenesis pathway remains fully active, thus resulting in the triad 
of hyperinsulinemia, hyperglycemia and hypertriglyceridemia typically observed 
in insulin resistant patients (Brown and Goldstein, 2008). This “selective insulin 
resistance” state is different from the “complete insulin resistance” phenotype 
observed in liver-specific insulin receptor knockout (LIRKO) mice, where insulin 
can no longer activate SREBP-1c-mediated lipid synthesis in liver (Biddinger et 
al., 2008). As a result, LIRKO mice exhibited hyperinsulinemia and 
hyperglycemia, but showed low levels of plasma and hepatic TAG. Therefore, 
selective insulin resistance in liver contributes to more severe metabolic defects. 
Hypertriglyceridemia causes ectopic deposition of lipid in organs other than white 
adipose tissue, which further promotes insulin resistance and insulin secretion, 
thus leading to a vicious cycle (Chavez and Summers, 2010). 
The mechanisms underlying the selective insulin resistance in liver remain 
unclear. One possibility is that, in addition to insulin signaling, SREBP-1c can 
also respond to other signals to induce lipogenesis (Ferre and Foufelle, 2010). 
Notably, mTORC1, which is greatly activated by the excessive nutrients (such as 
glucose and amino acids) available under obese and diabetic conditions (Zoncu 
et al., 2011), is one such candidate.  ER stress could also participate in the 
activation of SREBP-1c under insulin resistant conditions. It has been shown that 
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ER stress is induced in the liver of obese, insulin-resistant rodents (Ozcan et al., 
2004). Nonetheless, understanding the precise mechanisms underlying SREBP-
1c regulation in liver will provide new insight into disease biology as well as 
therapeutic targets for metabolic disorders. 
 
1.3 Thesis Overview 
PASK is proposed to play an important role in regulating cellular 
metabolism in response to nutrient status and other environmental conditions. 
Pask-/- mice are resistant to HFD-induced metabolic disorders. Interestingly, 
Pask-/- mice showed almost complete protection from hepatic steatosis, 
suggesting a potential role of PASK in regulating hepatic lipid metabolism. 
Hepatic steatosis is a major component of the metabolic syndrome and makes 
detrimental contributions to disease progression. However, the molecular 
mechanisms underlying hepatic steastosis remain unclear. Therefore, in this 
dissertation, we aimed to determine the mechanism whereby PASK regulates 
lipid metabolism in liver, as well as to explore the therapeutic potential of PASK in 
metabolic disorders. In Chapter 2, we describe the identification of SREBP-1 as a 
functional downstream target of PASK in mediating hepatic lipogenesis. We also 
show that pharmacological inhibition of PASK improved hepatic and whole-body 
dyslipidemia in animal models of diet-induced metabolic diseases. Additionally, 
we present two preliminary studies where we (1) examine the mechanism 
whereby PASK activates SREBP-1; and (2) investigate the upstream signaling 
pathway leading to SREBP-1 activation by PASK. Results from these studies not 
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only further our understanding of the physiological functions of PASK, but also 




Adams, C.M., Reitz, J., De Brabander, J.K., Feramisco, J.D., Li, L., Brown, M.S., 
and Goldstein, J.L. (2004). Cholesterol and 25-hydroxycholesterol inhibit 
activation of SREBPs by different mechanisms, both involving SCAP and Insigs. 
The Journal of Biological Chemistry 279, 52772-52780. 
Amemiya-Kudo, M., Shimano, H., Yoshikawa, T., Yahagi, N., Hasty, A.H., 
Okazaki, H., Tamura, Y., Shionoiri, F., Iizuka, Y., Ohashi, K., et al. (2000). 
Promoter analysis of the mouse sterol regulatory element-binding protein-1c 
gene. The Journal of Biological Chemistry 275, 31078-31085. 
Amezcua, C.A., Harper, S.M., Rutter, J., and Gardner, K.H. (2002). Structure and 
interactions of PAS kinase N-terminal PAS domain: model for intramolecular 
kinase regulation. Structure 10, 1349-1361. 
Bickle, M., Delley, P.A., Schmidt, A., and Hall, M.N. (1998). Cell wall integrity 
modulates RHO1 activity via the exchange factor ROM2. The EMBO Journal 17, 
2235-2245. 
Biddinger, S.B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J.T., Aleman, J.O., 
Suzuki, R., Scapa, E.F., Agarwal, C., Carey, M.C., Stephanopoulos, G., et al. 
(2008). Hepatic insulin resistance is sufficient to produce dyslipidemia and 
susceptibility to atherosclerosis. Cell Metabolism 7, 125-134. 
Bobrovnikova-Marjon, E., Hatzivassiliou, G., Grigoriadou, C., Romero, M., 
Cavener, D.R., Thompson, C.B., and Diehl, J.A. (2008). PERK-dependent 
regulation of lipogenesis during mouse mammary gland development and 
adipocyte differentiation. Proceedings of the National Academy of Sciences of 
the United States of America 105, 16314-16319. 
Briggs, M.R., Yokoyama, C., Wang, X., Brown, M.S., and Goldstein, J.L. (1993). 
Nuclear protein that binds sterol regulatory element of low density lipoprotein 
receptor promoter. I. Identification of the protein and delineation of its target 
nucleotide sequence. The Journal of Biological Chemistry 268, 14490-14496. 
42 
 
Brown, A.J., Sun, L., Feramisco, J.D., Brown, M.S., and Goldstein, J.L. (2002). 
Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP 
escort protein that regulates cholesterol metabolism. Molecular Cell 10, 237-245. 
Brown, M.S., and Goldstein, J.L. (1997). The SREBP pathway: regulation of 
cholesterol metabolism by proteolysis of a membrane-bound transcription factor. 
Cell 89, 331-340. 
Brown, M.S., and Goldstein, J.L. (2008). Selective versus total insulin resistance: 
a pathogenic paradox. Cell Metabolism 7, 95-96. 
Brown, M.S., and Goldstein, J.L. (2009). Cholesterol feedback: from 
Schoenheimer's bottle to Scap's MELADL. Journal of Lipid Research 50 Suppl, 
S15-27. 
Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., 
Cohen, J.C., Grundy, S.M., and Hobbs, H.H. (2004). Prevalence of hepatic 
steatosis in an urban population in the United States: impact of ethnicity. 
Hepatology 40, 1387-1395. 
Cardon, C.M., Beck, T., Hall, M.N., and Rutter, J. (2012). PAS kinase promotes 
cell survival and growth through activation of Rho1. Science Signaling 5, ra9. 
Cardon, C.M., and Rutter, J. (2012). PAS kinase: integrating nutrient sensing with 
nutrient partitioning. Seminars in Cell & Developmental Biology 23, 626-630. 
Chavez, J.A., and Summers, S.A. (2010). Lipid oversupply, selective insulin 
resistance, and lipotoxicity: molecular mechanisms. Biochimica et Biophysica 
Acta 1801, 252-265. 
Chen, G., Liang, G., Ou, J., Goldstein, J.L., and Brown, M.S. (2004). Central role 
for liver X receptor in insulin-mediated activation of Srebp-1c transcription and 
stimulation of fatty acid synthesis in liver. Proceedings of the National Academy 
of Sciences of the United States of America 101, 11245-11250. 
Cohen, J.C., Horton, J.D., and Hobbs, H.H. (2011). Human fatty liver disease: old 
questions and new insights. Science 332, 1519-1523. 
Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., and Hemmings, B.A. 
(1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein 
kinase B. Nature 378, 785-789. 
da Silva Xavier, G., Farhan, H., Kim, H., Caxaria, S., Johnson, P., Hughes, S., 
Bugliani, M., Marselli, L., Marchetti, P., Birzele, F., et al. (2011). Per-arnt-sim 
(PAS) domain-containing protein kinase is downregulated in human islets in type 
2 diabetes and regulates glucagon secretion. Diabetologia 54, 819-827. 
43 
 
da Silva Xavier, G., Rutter, J., and Rutter, G.A. (2004). Involvement of Per-Arnt-
Sim (PAS) kinase in the stimulation of preproinsulin and pancreatic duodenum 
homeobox 1 gene expression by glucose. Proceedings of the National Academy 
of Sciences of the United States of America 101, 8319-8324. 
Daran, J.M., Dallies, N., Thines-Sempoux, D., Paquet, V., and Francois, J. (1995). 
Genetic and biochemical characterization of the UGP1 gene encoding the UDP-
glucose pyrophosphorylase from Saccharomyces cerevisiae. European Journal 
of Biochemistry / FEBS 233, 520-530. 
DeBose-Boyd, R.A., Ou, J., Goldstein, J.L., and Brown, M.S. (2001). Expression 
of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat 
hepatoma cells requires endogenous LXR ligands. Proceedings of the National 
Academy of Sciences of the United States of America 98, 1477-1482. 
DeMille, D., Badal, B.D., Evans, J.B., Mathis, A.D., Anderson, J.F., and Grose, 
J.H. (2015). PAS kinase is activated by direct SNF1-dependent phosphorylation 
and mediates inhibition of TORC1 through the phosphorylation and activation of 
Pbp1. Molecular Biology of the Cell 26, 569-582. 
Diamond, R.H., Du, K., Lee, V.M., Mohn, K.L., Haber, B.A., Tewari, D.S., and 
Taub, R. (1993). Novel delayed-early and highly insulin-induced growth response 
genes. Identification of HRS, a potential regulator of alternative pre-mRNA 
splicing. The Journal of Biological Chemistry 268, 15185-15192. 
Dong, X.Y., and Tang, S.Q. (2010). Insulin-induced gene: a new regulator in lipid 
metabolism. Peptides 31, 2145-2150. 
Duncan, E.A., Brown, M.S., Goldstein, J.L., and Sakai, J. (1997). Cleavage site 
for sterol-regulated protease localized to a leu-Ser bond in the lumenal loop of 
sterol regulatory element-binding protein-2. The Journal of Biological Chemistry 
272, 12778-12785. 
Duncan, E.A., Dave, U.P., Sakai, J., Goldstein, J.L., and Brown, M.S. (1998). 
Second-site cleavage in sterol regulatory element-binding protein occurs at 
transmembrane junction as determined by cysteine panning. The Journal of 
Biological Chemistry 273, 17801-17809. 
Duvel, K., Yecies, J.L., Menon, S., Raman, P., Lipovsky, A.I., Souza, A.L., 
Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010). Activation of a 
metabolic gene regulatory network downstream of mTOR complex 1. Molecular 
Cell 39, 171-183. 
Engelking, L.J., Kuriyama, H., Hammer, R.E., Horton, J.D., Brown, M.S., 
Goldstein, J.L., and Liang, G. (2004). Overexpression of Insig-1 in the livers of 
44 
 
transgenic mice inhibits SREBP processing and reduces insulin-stimulated 
lipogenesis. The Journal of Clinical Investigation 113, 1168-1175. 
Engelking, L.J., Liang, G., Hammer, R.E., Takaishi, K., Kuriyama, H., Evers, B.M., 
Li, W.P., Horton, J.D., Goldstein, J.L., and Brown, M.S. (2005). Schoenheimer 
effect explained--feedback regulation of cholesterol synthesis in mice mediated 
by Insig proteins. The Journal of Clinical Investigation 115, 2489-2498. 
Espenshade, P.J., Li, W.P., and Yabe, D. (2002). Sterols block binding of COPII 
proteins to SCAP, thereby controlling SCAP sorting in ER. Proceedings of the 
National Academy of Sciences of the United States of America 99, 11694-11699. 
Feramisco, J.D., Goldstein, J.L., and Brown, M.S. (2004). Membrane topology of 
human insig-1, a protein regulator of lipid synthesis. The Journal of Biological 
Chemistry 279, 8487-8496. 
Ferre, P., and Foufelle, F. (2010). Hepatic steatosis: a role for de novo 
lipogenesis and the transcription factor SREBP-1c. Diabetes, Obesity & 
Metabolism 12 Suppl 2, 83-92. 
Giandomenico, V., Simonsson, M., Gronroos, E., and Ericsson, J. (2003). 
Coactivator-dependent acetylation stabilizes members of the SREBP family of 
transcription factors. Molecular and Cellular Biology 23, 2587-2599. 
Goldstein, J.L., DeBose-Boyd, R.A., and Brown, M.S. (2006). Protein sensors for 
membrane sterols. Cell 124, 35-46. 
Gong, Y., Lee, J.N., Lee, P.C., Goldstein, J.L., Brown, M.S., and Ye, J. (2006). 
Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent 
mechanism for feedback control of cholesterol synthesis and uptake. Cell 
Metabolism 3, 15-24. 
Grose, J.H., Sundwall, E., and Rutter, J. (2009). Regulation and function of yeast 
PAS kinase: a role in the maintenance of cellular integrity. Cell Cycle 8, 1824-
1832. 
Hannah, V.C., Ou, J., Luong, A., Goldstein, J.L., and Brown, M.S. (2001). 
Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two 
mechanisms in HEK-293 cells. The Journal of Biological Chemistry 276, 4365-
4372. 
Hao, H.X., Cardon, C.M., Swiatek, W., Cooksey, R.C., Smith, T.L., Wilde, J., 
Boudina, S., Abel, E.D., McClain, D.A., and Rutter, J. (2007). PAS kinase is 
required for normal cellular energy balance. Proceedings of the National 
Academy of Sciences of the United States of America 104, 15466-15471. 
45 
 
Hao, H.X., and Rutter, J. (2008). The role of PAS kinase in regulating energy 
metabolism. IUBMB Life 60, 204-209. 
Hao, Y., Chun, A., Cheung, K., Rashidi, B., and Yang, X. (2008). Tumor 
suppressor LATS1 is a negative regulator of oncogene YAP. The Journal of 
Biological Chemistry 283, 5496-5509. 
Hayden, M.S., and Ghosh, S. (2012). NF-kappaB, the first quarter-century: 
remarkable progress and outstanding questions. Genes & Development 26, 203-
234. 
Hegarty, B.D., Bobard, A., Hainault, I., Ferre, P., Bossard, P., and Foufelle, F. 
(2005). Distinct roles of insulin and liver X receptor in the induction and cleavage 
of sterol regulatory element-binding protein-1c. Proceedings of the National 
Academy of Sciences of the United States of America 102, 791-796. 
Helliwell, S.B., Schmidt, A., Ohya, Y., and Hall, M.N. (1998). The Rho1 effector 
Pkc1, but not Bni1, mediates signalling from Tor2 to the actin cytoskeleton. 
Current Biology: CB 8, 1211-1214. 
Helliwell, S.B., Wagner, P., Kunz, J., Deuter-Reinhard, M., Henriquez, R., and 
Hall, M.N. (1994). TOR1 and TOR2 are structurally and functionally similar but 
not identical phosphatidylinositol kinase homologues in yeast. Molecular Biology 
of the Cell 5, 105-118. 
Hirano, Y., Yoshida, M., Shimizu, M., and Sato, R. (2001). Direct demonstration 
of rapid degradation of nuclear sterol regulatory element-binding proteins by the 
ubiquitin-proteasome pathway. The Journal of Biological Chemistry 276, 36431-
36437. 
Horton, J.D., Goldstein, J.L., and Brown, M.S. (2002). SREBPs: activators of the 
complete program of cholesterol and fatty acid synthesis in the liver. The Journal 
of Clinical Investigation 109, 1125-1131. 
Horton, J.D., Shimomura, I., Brown, M.S., Hammer, R.E., Goldstein, J.L., and 
Shimano, H. (1998). Activation of cholesterol synthesis in preference to fatty acid 
synthesis in liver and adipose tissue of transgenic mice overproducing sterol 
regulatory element-binding protein-2. The Journal of Clinical Investigation 101, 
2331-2339. 
Hotamisligil, G.S., and Erbay, E. (2008). Nutrient sensing and inflammation in 
metabolic diseases. Nature Reviews Immunology 8, 923-934. 
Hua, X., Nohturfft, A., Goldstein, J.L., and Brown, M.S. (1996). Sterol resistance 




Hua, X., Sakai, J., Ho, Y.K., Goldstein, J.L., and Brown, M.S. (1995a). Hairpin 
orientation of sterol regulatory element-binding protein-2 in cell membranes as 
determined by protease protection. The Journal of Biological Chemistry 270, 
29422-29427. 
Hua, X., Wu, J., Goldstein, J.L., Brown, M.S., and Hobbs, H.H. (1995b). Structure 
of the human gene encoding sterol regulatory element binding protein-1 
(SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 
and 22q13. Genomics 25, 667-673. 
Humphrey, R.K., Yu, S.M., Flores, L.E., and Jhala, U.S. (2010). Glucose 
regulates steady-state levels of PDX1 via the reciprocal actions of GSK3 and 
AKT kinases. The Journal of Biological Chemistry 285, 3406-3416. 
Ikeda, Y., Demartino, G.N., Brown, M.S., Lee, J.N., Goldstein, J.L., and Ye, J. 
(2009). Regulated endoplasmic reticulum-associated degradation of a polytopic 
protein: p97 recruits proteasomes to Insig-1 before extraction from membranes. 
The Journal of Biological Chemistry 284, 34889-34900. 
Im, S.S., Yousef, L., Blaschitz, C., Liu, J.Z., Edwards, R.A., Young, S.G., 
Raffatellu, M., and Osborne, T.F. (2011). Linking lipid metabolism to the innate 
immune response in macrophages through sterol regulatory element binding 
protein-1a. Cell Metabolism 13, 540-549. 
Ishimoto, K., Nakamura, H., Tachibana, K., Yamasaki, D., Ota, A., Hirano, K., 
Tanaka, T., Hamakubo, T., Sakai, J., Kodama, T., et al. (2009). Sterol-mediated 
regulation of human lipin 1 gene expression in hepatoblastoma cells. The Journal 
of Biological Chemistry 284, 22195-22205. 
Johnson, L.N., Noble, M.E., and Owen, D.J. (1996). Active and inactive protein 
kinases: structural basis for regulation. Cell 85, 149-158. 
Kahn, B.B., Alquier, T., Carling, D., and Hardie, D.G. (2005). AMP-activated 
protein kinase: ancient energy gauge provides clues to modern understanding of 
metabolism. Cell Metabolism 1, 15-25. 
Kammoun, H.L., Chabanon, H., Hainault, I., Luquet, S., Magnan, C., Koike, T., 
Ferre, P., and Foufelle, F. (2009). GRP78 expression inhibits insulin and ER 
stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. The 
Journal of Clinical Investigation 119, 1201-1215. 
Kikani, C.K., Antonysamy, S.A., Bonanno, J.B., Romero, R., Zhang, F.F., Russell, 
M., Gheyi, T., Iizuka, M., Emtage, S., Sauder, J.M., et al. (2010). Structural bases 
of PAS domain-regulated kinase (PASK) activation in the absence of activation 
loop phosphorylation. The Journal of Biological Chemistry 285, 41034-41043. 
47 
 
Kim, J.B., Spotts, G.D., Halvorsen, Y.D., Shih, H.M., Ellenberger, T., Towle, H.C., 
and Spiegelman, B.M. (1995). Dual DNA binding specificity of ADD1/SREBP1 
controlled by a single amino acid in the basic helix-loop-helix domain. Molecular 
and Cellular Biology 15, 2582-2588. 
Kim, K.H., Song, M.J., Yoo, E.J., Choe, S.S., Park, S.D., and Kim, J.B. (2004). 
Regulatory role of glycogen synthase kinase 3 for transcriptional activity of 
ADD1/SREBP1c. The Journal of Biological Chemistry 279, 51999-52006. 
Kitanishi, K., Igarashi, J., Hayasaka, K., Hikage, N., Saiful, I., Yamauchi, S., 
Uchida, T., Ishimori, K., and Shimizu, T. (2008). Heme-binding characteristics of 
the isolated PAS-A domain of mouse Per2, a transcriptional regulatory factor 
associated with circadian rhythms. Biochemistry 47, 6157-6168. 
Krycer, J.R., Sharpe, L.J., Luu, W., and Brown, A.J. (2010). The Akt-SREBP 
nexus: cell signaling meets lipid metabolism. Trends in Endocrinology and 
Metabolism: TEM 21, 268-276. 
Leavens, K.F., Easton, R.M., Shulman, G.I., Previs, S.F., and Birnbaum, M.J. 
(2009). Akt2 is required for hepatic lipid accumulation in models of insulin 
resistance. Cell Metabolism 10, 405-418. 
Lee, J.N., Gong, Y., Zhang, X., and Ye, J. (2006a). Proteasomal degradation of 
ubiquitinated Insig proteins is determined by serine residues flanking 
ubiquitinated lysines. Proceedings of the National Academy of Sciences of the 
United States of America 103, 4958-4963. 
Lee, J.N., Song, B., DeBose-Boyd, R.A., and Ye, J. (2006b). Sterol-regulated 
degradation of Insig-1 mediated by the membrane-bound ubiquitin ligase gp78. 
The Journal of Biological Chemistry 281, 39308-39315. 
Lee, J.N., and Ye, J. (2004). Proteolytic activation of sterol regulatory element-
binding protein induced by cellular stress through depletion of Insig-1. The 
Journal of Biological Chemistry 279, 45257-45265. 
Lee, J.N., Zhang, X., Feramisco, J.D., Gong, Y., and Ye, J. (2008). Unsaturated 
fatty acids inhibit proteasomal degradation of Insig-1 at a postubiquitination step. 
The Journal of Biological Chemistry 283, 33772-33783. 
Lewis, C.A., Griffiths, B., Santos, C.R., Pende, M., and Schulze, A. (2011). 
Genetic ablation of S6-kinase does not prevent processing of SREBP1. 
Advances in Enzyme Regulation 51, 280-290. 
Li, S., Brown, M.S., and Goldstein, J.L. (2010). Bifurcation of insulin signaling 
pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not 
48 
 
inhibition of gluconeogenesis. Proceedings of the National Academy of Sciences 
of the United States of America 107, 3441-3446. 
Li, Y., Xu, S., Mihaylova, M.M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., 
Lefai, E., Shyy, J.Y., et al. (2011). AMPK phosphorylates and inhibits SREBP 
activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-
resistant mice. Cell Metabolism 13, 376-388. 
Liang, G., Yang, J., Horton, J.D., Hammer, R.E., Goldstein, J.L., and Brown, M.S. 
(2002). Diminished hepatic response to fasting/refeeding and liver X receptor 
agonists in mice with selective deficiency of sterol regulatory element-binding 
protein-1c. The Journal of Biological Chemistry 277, 9520-9528. 
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J.L., Bonenfant, 
D., Oppliger, W., Jenoe, P., and Hall, M.N. (2002). Two TOR complexes, only 
one of which is rapamycin sensitive, have distinct roles in cell growth control. 
Molecular Cell 10, 457-468. 
Lu, M., and Shyy, J.Y. (2006). Sterol regulatory element-binding protein 1 is 
negatively modulated by PKA phosphorylation. American Journal of Physiology 
Cell Physiology 290, C1477-1486. 
Matsuda, M., Korn, B.S., Hammer, R.E., Moon, Y.A., Komuro, R., Horton, J.D., 
Goldstein, J.L., Brown, M.S., and Shimomura, I. (2001). SREBP cleavage-
activating protein (SCAP) is required for increased lipid synthesis in liver induced 
by cholesterol deprivation and insulin elevation. Genes & Development 15, 1206-
1216. 
Mazanka, E., Alexander, J., Yeh, B.J., Charoenpong, P., Lowery, D.M., Yaffe, M., 
and Weiss, E.L. (2008). The NDR/LATS family kinase Cbk1 directly controls 
transcriptional asymmetry. PLoS Biology 6, e203. 
Monson, E.K., Ditta, G.S., and Helinski, D.R. (1995). The oxygen sensor protein, 
FixL, of Rhizobium meliloti. Role of histidine residues in heme binding, 
phosphorylation, and signal transduction. The Journal of Biological Chemistry 
270, 5243-5250. 
Moon, Y.A., Liang, G., Xie, X., Frank-Kamenetsky, M., Fitzgerald, K., Koteliansky, 
V., Brown, M.S., Goldstein, J.L., and Horton, J.D. (2012). The Scap/SREBP 
pathway is essential for developing diabetic fatty liver and carbohydrate-induced 
hypertriglyceridemia in animals. Cell Metabolism 15, 240-246. 
Murre, C., Bain, G., van Dijk, M.A., Engel, I., Furnari, B.A., Massari, M.E., 
Matthews, J.R., Quong, M.W., Rivera, R.R., and Stuiver, M.H. (1994). Structure 




Nagoshi, E., and Yoneda, Y. (2001). Dimerization of sterol regulatory element-
binding protein 2 via the helix-loop-helix-leucine zipper domain is a prerequisite 
for its nuclear localization mediated by importin beta. Molecular and Cellular 
Biology 21, 2779-2789. 
Nambu, J.R., Lewis, J.O., Wharton, K.A., Jr., and Crews, S.T. (1991). The 
Drosophila single-minded gene encodes a helix-loop-helix protein that acts as a 
master regulator of CNS midline development. Cell 67, 1157-1167. 
Ness, G.C., Pendleton, L.C., Li, Y.C., and Chiang, J.Y. (1990). Effect of thyroid 
hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA 
reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA 
levels in hypophysectomized rats. Biochemical and Biophysical Research 
Communications 172, 1150-1156. 
Nohturfft, A., Brown, M.S., and Goldstein, J.L. (1998). Topology of SREBP 
cleavage-activating protein, a polytopic membrane protein with a sterol-sensing 
domain. The Journal of Biological Chemistry 273, 17243-17250. 
Nohturfft, A., Yabe, D., Goldstein, J.L., Brown, M.S., and Espenshade, P.J. 
(2000). Regulated step in cholesterol feedback localized to budding of SCAP 
from ER membranes. Cell 102, 315-323. 
Oliner, J.D., Andresen, J.M., Hansen, S.K., Zhou, S., and Tjian, R. (1996). 
SREBP transcriptional activity is mediated through an interaction with the CREB-
binding protein. Genes & Development 10, 2903-2911. 
Osborne, T.F., and Espenshade, P.J. (2009). Evolutionary conservation and 
adaptation in the mechanism that regulates SREBP action: what a long, strange 
tRIP it's been. Genes & Development 23, 2578-2591. 
Ou, J., Tu, H., Shan, B., Luk, A., DeBose-Boyd, R.A., Bashmakov, Y., Goldstein, 
J.L., and Brown, M.S. (2001). Unsaturated fatty acids inhibit transcription of the 
sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing 
ligand-dependent activation of the LXR. Proceedings of the National Academy of 
Sciences of the United States of America 98, 6027-6032. 
Owen, J.L., Zhang, Y., Bae, S.H., Farooqi, M.S., Liang, G., Hammer, R.E., 
Goldstein, J.L., and Brown, M.S. (2012). Insulin stimulation of SREBP-1c 
processing in transgenic rat hepatocytes requires p70 S6-kinase. Proceedings of 
the National Academy of Sciences of the United States of America 109, 16184-
16189. 
Ozcan, U., Cao, Q., Yilmaz, E., Lee, A.H., Iwakoshi, N.N., Ozdelen, E., Tuncman, 
G., Gorgun, C., Glimcher, L.H., and Hotamisligil, G.S. (2004). Endoplasmic 
50 
 
reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 
457-461. 
Pai, J.T., Guryev, O., Brown, M.S., and Goldstein, J.L. (1998). Differential 
stimulation of cholesterol and unsaturated fatty acid biosynthesis in cells 
expressing individual nuclear sterol regulatory element-binding proteins. The 
Journal of Biological Chemistry 273, 26138-26148. 
Parraga, A., Bellsolell, L., Ferre-D'Amare, A.R., and Burley, S.K. (1998). Co-
crystal structure of sterol regulatory element binding protein 1a at 2.3 A resolution. 
Structure 6, 661-672. 
Peng, Y., Schwarz, E.J., Lazar, M.A., Genin, A., Spinner, N.B., and Taub, R. 
(1997). Cloning, human chromosomal assignment, and adipose and hepatic 
expression of the CL-6/INSIG1 gene. Genomics 43, 278-284. 
Peterson, T.R., Sengupta, S.S., Harris, T.E., Carmack, A.E., Kang, S.A., 
Balderas, E., Guertin, D.A., Madden, K.L., Carpenter, A.E., Finck, B.N., et al. 
(2011). mTOR complex 1 regulates lipin 1 localization to control the SREBP 
pathway. Cell 146, 408-420. 
Porstmann, T., Santos, C.R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, 
J.R., Chung, Y.L., and Schulze, A. (2008). SREBP activity is regulated by 
mTORC1 and contributes to Akt-dependent cell growth. Cell Metabolism 8, 224-
236. 
Punga, T., Bengoechea-Alonso, M.T., and Ericsson, J. (2006). Phosphorylation 
and ubiquitination of the transcription factor sterol regulatory element-binding 
protein-1 in response to DNA binding. The Journal of Biological Chemistry 281, 
25278-25286. 
Quesada, I., Tuduri, E., Ripoll, C., and Nadal, A. (2008). Physiology of the 
pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and 
diabetes. The Journal of Endocrinology 199, 5-19. 
Radhakrishnan, A., Ikeda, Y., Kwon, H.J., Brown, M.S., and Goldstein, J.L. 
(2007). Sterol-regulated transport of SREBPs from endoplasmic reticulum to 
Golgi: oxysterols block transport by binding to Insig. Proceedings of the National 
Academy of Sciences of the United States of America 104, 6511-6518. 
Radhakrishnan, A., Sun, L.P., Kwon, H.J., Brown, M.S., and Goldstein, J.L. 
(2004). Direct binding of cholesterol to the purified membrane region of SCAP: 
mechanism for a sterol-sensing domain. Molecular Cell 15, 259-268. 
Rawson, R.B., Cheng, D., Brown, M.S., and Goldstein, J.L. (1998). Isolation of 
cholesterol-requiring mutant Chinese hamster ovary cells with defects in 
51 
 
cleavage of sterol regulatory element-binding proteins at site 1. The Journal of 
Biological Chemistry 273, 28261-28269. 
Rawson, R.B., Zelenski, N.G., Nijhawan, D., Ye, J., Sakai, J., Hasan, M.T., 
Chang, T.Y., Brown, M.S., and Goldstein, J.L. (1997). Complementation cloning 
of S2P, a gene encoding a putative metalloprotease required for intramembrane 
cleavage of SREBPs. Molecular Cell 1, 47-57. 
Repa, J.J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.M., Shimomura, I., 
Shan, B., Brown, M.S., Goldstein, J.L., and Mangelsdorf, D.J. (2000). Regulation 
of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by 
oxysterol receptors, LXRalpha and LXRbeta. Genes & Development 14, 2819-
2830. 
Ron, D., and Walter, P. (2007). Signal integration in the endoplasmic reticulum 
unfolded protein response. Nature Reviews Molecular Cell Biology 8, 519-529. 
Ruderman, N.B., Xu, X.J., Nelson, L., Cacicedo, J.M., Saha, A.K., Lan, F., and 
Ido, Y. (2010). AMPK and SIRT1: a long-standing partnership? American journal 
of physiology Endocrinology and Metabolism 298, E751-760. 
Rutter, J., Michnoff, C.H., Harper, S.M., Gardner, K.H., and McKnight, S.L. 
(2001). PAS kinase: an evolutionarily conserved PAS domain-regulated 
serine/threonine kinase. Proceedings of the National Academy of Sciences of the 
United States of America 98, 8991-8996. 
Rutter, J., Probst, B.L., and McKnight, S.L. (2002). Coordinate regulation of sugar 
flux and translation by PAS kinase. Cell 111, 17-28. 
Sabatini, P.V., and Lynn, F.C. (2015). All-encomPASsing regulation of beta-cells: 
PAS domain proteins in beta-cell dysfunction and diabetes. Trends in 
Endocrinology and Metabolism: TEM 26, 49-57. 
Sakai, J., Duncan, E.A., Rawson, R.B., Hua, X., Brown, M.S., and Goldstein, J.L. 
(1996). Sterol-regulated release of SREBP-2 from cell membranes requires two 
sequential cleavages, one within a transmembrane segment. Cell 85, 1037-1046. 
Sakai, J., Nohturfft, A., Cheng, D., Ho, Y.K., Brown, M.S., and Goldstein, J.L. 
(1997). Identification of complexes between the COOH-terminal domains of sterol 
regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating 
protein. The Journal of Biological Chemistry 272, 20213-20221. 
Sakai, J., Nohturfft, A., Goldstein, J.L., and Brown, M.S. (1998a). Cleavage of 
sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction 
with SREBP cleavage-activating protein. Evidence from in vivo competition 
studies. The Journal of Biological Chemistry 273, 5785-5793. 
52 
 
Sakai, J., Rawson, R.B., Espenshade, P.J., Cheng, D., Seegmiller, A.C., 
Goldstein, J.L., and Brown, M.S. (1998b). Molecular identification of the sterol-
regulated luminal protease that cleaves SREBPs and controls lipid composition 
of animal cells. Molecular Cell 2, 505-514. 
Saltiel, A.R., and Kahn, C.R. (2001). Insulin signalling and the regulation of 
glucose and lipid metabolism. Nature 414, 799-806. 
Samuel, V.T., and Shulman, G.I. (2012). Mechanisms for insulin resistance: 
common threads and missing links. Cell 148, 852-871. 
Sarbassov, D.D., Ali, S.M., and Sabatini, D.M. (2005). Growing roles for the 
mTOR pathway. Current Opinion in Cell Biology 17, 596-603. 
Sato, R., Inoue, J., Kawabe, Y., Kodama, T., Takano, T., and Maeda, M. (1996). 
Sterol-dependent transcriptional regulation of sterol regulatory element-binding 
protein-2. The Journal of Biological Chemistry 271, 26461-26464. 
Sato, R., Yang, J., Wang, X., Evans, M.J., Ho, Y.K., Goldstein, J.L., and Brown, 
M.S. (1994). Assignment of the membrane attachment, DNA binding, and 
transcriptional activation domains of sterol regulatory element-binding protein-1 
(SREBP-1). The Journal of Biological Chemistry 269, 17267-17273. 
Semache, M., Zarrouki, B., Fontes, G., Fogarty, S., Kikani, C., Chawki, M.B., 
Rutter, J., and Poitout, V. (2013). Per-Arnt-Sim kinase regulates pancreatic 
duodenal homeobox-1 protein stability via phosphorylation of glycogen synthase 
kinase 3beta in pancreatic beta-cells. The Journal of Biological Chemistry 288, 
24825-24833. 
Semplici, F., Vaxillaire, M., Fogarty, S., Semache, M., Bonnefond, A., Fontes, G., 
Philippe, J., Meur, G., Diraison, F., Sessions, R.B., et al. (2011). Human mutation 
within Per-Arnt-Sim (PAS) domain-containing protein kinase (PASK) causes 
basal insulin hypersecretion. The Journal of Biological Chemistry 286, 44005-
44014. 
Seo, Y.K., Jeon, T.I., Chong, H.K., Biesinger, J., Xie, X., and Osborne, T.F. 
(2011). Genome-wide localization of SREBP-2 in hepatic chromatin predicts a 
role in autophagy. Cell Metabolism 13, 367-375. 
Shimano, H., Horton, J.D., Hammer, R.E., Shimomura, I., Brown, M.S., and 
Goldstein, J.L. (1996). Overproduction of cholesterol and fatty acids causes 
massive liver enlargement in transgenic mice expressing truncated SREBP-1a. 
The Journal of Clinical Investigation 98, 1575-1584. 
Shimano, H., Horton, J.D., Shimomura, I., Hammer, R.E., Brown, M.S., and 
Goldstein, J.L. (1997a). Isoform 1c of sterol regulatory element binding protein is 
53 
 
less active than isoform 1a in livers of transgenic mice and in cultured cells. The 
Journal of Clinical Investigation 99, 846-854. 
Shimano, H., Shimomura, I., Hammer, R.E., Herz, J., Goldstein, J.L., Brown, 
M.S., and Horton, J.D. (1997b). Elevated levels of SREBP-2 and cholesterol 
synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 
gene. The Journal of Clinical Investigation 100, 2115-2124. 
Shimomura, I., Bashmakov, Y., and Horton, J.D. (1999a). Increased levels of 
nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes 
mellitus. The Journal of Biological Chemistry 274, 30028-30032. 
Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J.D., Brown, M.S., and 
Goldstein, J.L. (1999b). Insulin selectively increases SREBP-1c mRNA in the 
livers of rats with streptozotocin-induced diabetes. Proceedings of the National 
Academy of Sciences of the United States of America 96, 13656-13661. 
Shimomura, I., Shimano, H., Horton, J.D., Goldstein, J.L., and Brown, M.S. 
(1997). Differential expression of exons 1a and 1c in mRNAs for sterol regulatory 
element binding protein-1 in human and mouse organs and cultured cells. The 
Journal of Clinical Investigation 99, 838-845. 
Shin, D.J., and Osborne, T.F. (2003). Thyroid hormone regulation and cholesterol 
metabolism are connected through Sterol Regulatory Element-Binding Protein-2 
(SREBP-2). The Journal of Biological Chemistry 278, 34114-34118. 
Smith, J.R., Osborne, T.F., Goldstein, J.L., and Brown, M.S. (1990). Identification 
of nucleotides responsible for enhancer activity of sterol regulatory element in low 
density lipoprotein receptor gene. The Journal of Biological Chemistry 265, 2306-
2310. 
Smith, T.L., and Rutter, J. (2007). Regulation of glucose partitioning by PAS 
kinase and Ugp1 phosphorylation. Molecular Cell 26, 491-499. 
Soshilov, A., and Denison, M.S. (2008). Role of the Per/Arnt/Sim domains in 
ligand-dependent transformation of the aryl hydrocarbon receptor. The Journal of 
Biological Chemistry 283, 32995-33005. 
Stephenson, K., and Hoch, J.A. (2001). PAS-A domain of phosphorelay sensor 
kinase A: a catalytic ATP-binding domain involved in the initiation of development 
in Bacillus subtilis. Proceedings of the National Academy of Sciences of the 
United States of America 98, 15251-15256. 
Sun, L.P., Li, L., Goldstein, J.L., and Brown, M.S. (2005). Insig required for sterol-
mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. The 
Journal of Biological Chemistry 280, 26483-26490. 
54 
 
Sun, L.P., Seemann, J., Goldstein, J.L., and Brown, M.S. (2007). Sterol-regulated 
transport of SREBPs from endoplasmic reticulum to Golgi: Insig renders sorting 
signal in Scap inaccessible to COPII proteins. Proceedings of the National 
Academy of Sciences of the United States of America 104, 6519-6526. 
Sundqvist, A., Bengoechea-Alonso, M.T., Ye, X., Lukiyanchuk, V., Jin, J., Harper, 
J.W., and Ericsson, J. (2005). Control of lipid metabolism by phosphorylation-
dependent degradation of the SREBP family of transcription factors by 
SCF(Fbw7). Cell Metabolism 1, 379-391. 
Sundqvist, A., and Ericsson, J. (2003). Transcription-dependent degradation 
controls the stability of the SREBP family of transcription factors. Proceedings of 
the National Academy of Sciences of the United States of America 100, 13833-
13838. 
Taylor, B.L., and Zhulin, I.B. (1999). PAS domains: internal sensors of oxygen, 
redox potential, and light. Microbiology and Molecular Biology Reviews: MMBR 
63, 479-506. 
Tolman, K.G., Fonseca, V., Dalpiaz, A., and Tan, M.H. (2007). Spectrum of liver 
disease in type 2 diabetes and management of patients with diabetes and liver 
disease. Diabetes Care 30, 734-743. 
Toth, J.I., Datta, S., Athanikar, J.N., Freedman, L.P., and Osborne, T.F. (2004). 
Selective coactivator interactions in gene activation by SREBP-1a and -1c. 
Molecular and Cellular Biology 24, 8288-8300. 
Vadlakonda, L., Dash, A., Pasupuleti, M., Anil Kumar, K., and Reddanna, P. 
(2013). The Paradox of Akt-mTOR Interactions. Frontiers in Oncology 3, 165. 
Walker, A.K., Jacobs, R.L., Watts, J.L., Rottiers, V., Jiang, K., Finnegan, D.M., 
Shioda, T., Hansen, M., Yang, F., Niebergall, L.J., et al. (2011). A conserved 
SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in 
metazoans. Cell 147, 840-852. 
Walker, A.K., Yang, F., Jiang, K., Ji, J.Y., Watts, J.L., Purushotham, A., Boss, O., 
Hirsch, M.L., Ribich, S., Smith, J.J., et al. (2010). Conserved role of SIRT1 
orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. 
Genes & Development 24, 1403-1417. 
Wang, X., Briggs, M.R., Hua, X., Yokoyama, C., Goldstein, J.L., and Brown, M.S. 
(1993). Nuclear protein that binds sterol regulatory element of low density 
lipoprotein receptor promoter. II. Purification and characterization. The Journal of 
Biological Chemistry 268, 14497-14504. 
55 
 
Wang, X., Sato, R., Brown, M.S., Hua, X., and Goldstein, J.L. (1994). SREBP-1, 
a membrane-bound transcription factor released by sterol-regulated proteolysis. 
Cell 77, 53-62. 
Werstuck, G.H., Lentz, S.R., Dayal, S., Hossain, G.S., Sood, S.K., Shi, Y.Y., 
Zhou, J., Maeda, N., Krisans, S.K., Malinow, M.R., et al. (2001). Homocysteine-
induced endoplasmic reticulum stress causes dysregulation of the cholesterol 
and triglyceride biosynthetic pathways. The Journal of Clinical Investigation 107, 
1263-1273. 
Yabe, D., Brown, M.S., and Goldstein, J.L. (2002). Insig-2, a second endoplasmic 
reticulum protein that binds SCAP and blocks export of sterol regulatory element-
binding proteins. Proceedings of the National Academy of Sciences of the United 
States of America 99, 12753-12758. 
Yabe, D., Komuro, R., Liang, G., Goldstein, J.L., and Brown, M.S. (2003). Liver-
specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid 
synthesis. Proceedings of the National Academy of Sciences of the United States 
of America 100, 3155-3160. 
Yahagi, N., Shimano, H., Hasty, A.H., Matsuzaka, T., Ide, T., Yoshikawa, T., 
Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y., et al. (2002). Absence 
of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers 
but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. The Journal of 
Biological Chemistry 277, 19353-19357. 
Yamamoto, T., Shimano, H., Inoue, N., Nakagawa, Y., Matsuzaka, T., Takahashi, 
A., Yahagi, N., Sone, H., Suzuki, H., Toyoshima, H., et al. (2007). Protein kinase 
A suppresses sterol regulatory element-binding protein-1C expression via 
phosphorylation of liver X receptor in the liver. The Journal of Biological 
Chemistry 282, 11687-11695. 
Yang, F., Vought, B.W., Satterlee, J.S., Walker, A.K., Jim Sun, Z.Y., Watts, J.L., 
DeBeaumont, R., Saito, R.M., Hyberts, S.G., Yang, S., et al. (2006). An 
ARC/Mediator subunit required for SREBP control of cholesterol and lipid 
homeostasis. Nature 442, 700-704. 
Yang, J., Goldstein, J.L., Hammer, R.E., Moon, Y.A., Brown, M.S., and Horton, 
J.D. (2001). Decreased lipid synthesis in livers of mice with disrupted Site-1 
protease gene. Proceedings of the National Academy of Sciences of the United 
States of America 98, 13607-13612. 
Yang, T., Espenshade, P.J., Wright, M.E., Yabe, D., Gong, Y., Aebersold, R., 
Goldstein, J.L., and Brown, M.S. (2002). Crucial step in cholesterol homeostasis: 
sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates 
retention of SREBPs in ER. Cell 110, 489-500. 
56 
 
Ye, J., and DeBose-Boyd, R.A. (2011). Regulation of cholesterol and fatty acid 
synthesis. Cold Spring Harbor Perspectives in Biology 3. 
Yecies, J.L., Zhang, H.H., Menon, S., Liu, S., Yecies, D., Lipovsky, A.I., Gorgun, 
C., Kwiatkowski, D.J., Hotamisligil, G.S., Lee, C.H., et al. (2011). Akt stimulates 
hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and 
independent pathways. Cell Metabolism 14, 21-32. 
Yellaturu, C.R., Deng, X., Cagen, L.M., Wilcox, H.G., Mansbach, C.M., 2nd, 
Siddiqi, S.A., Park, E.A., Raghow, R., and Elam, M.B. (2009a). Insulin enhances 
post-translational processing of nascent SREBP-1c by promoting its 
phosphorylation and association with COPII vesicles. The Journal of Biological 
Chemistry 284, 7518-7532. 
Yellaturu, C.R., Deng, X., Park, E.A., Raghow, R., and Elam, M.B. (2009b). 
Insulin enhances the biogenesis of nuclear sterol regulatory element-binding 
protein (SREBP)-1c by posttranscriptional down-regulation of Insig-2A and its 
dissociation from SREBP cleavage-activating protein (SCAP).SREBP-1c 
complex. The Journal of Biological Chemistry 284, 31726-31734. 
Yoshikawa, T., Shimano, H., Amemiya-Kudo, M., Yahagi, N., Hasty, A.H., 
Matsuzaka, T., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., et al. (2001). 
Identification of liver X receptor-retinoid X receptor as an activator of the sterol 
regulatory element-binding protein 1c gene promoter. Molecular and Cellular 
Biology 21, 2991-3000. 
Zelenski, N.G., Rawson, R.B., Brown, M.S., and Goldstein, J.L. (1999). 
Membrane topology of S2P, a protein required for intramembranous cleavage of 
sterol regulatory element-binding proteins. The Journal of Biological Chemistry 
274, 21973-21980. 
Zhang, C., Shin, D.J., and Osborne, T.F. (2005). A simple promoter containing 
two Sp1 sites controls the expression of sterol-regulatory-element-binding protein 
1a (SREBP-1a). The Biochemical Journal 386, 161-168. 
Zhao, X., Feng, D., Wang, Q., Abdulla, A., Xie, X.J., Zhou, J., Sun, Y., Yang, E.S., 
Liu, L.P., Vaitheesvaran, B., et al. (2012). Regulation of lipogenesis by cyclin-
dependent kinase 8-mediated control of SREBP-1. The Journal of Clinical 
Investigation 122, 2417-2427. 
Zhulin, I.B., Taylor, B.L., and Dixon, R. (1997). PAS domain S-boxes in Archaea, 




Zoncu, R., Efeyan, A., and Sabatini, D.M. (2011). mTOR: from growth signal 
integration to cancer, diabetes and ageing. Nature Reviews Molecular Cell 






PAS KINASE DRIVES LIPOGENESIS THROUGH SREBP-1  
MATURATION 
 
Xiaoying Wu, Donna Romero, Wojciech I. Swiatek, Irene Dorweiler, Chintan K. 
Kikani, Hana Sabic, Ben S. Zweifel, John McKearn, Jeremy T. Blitzer, G. Allen 






Reprinted from Cell Reports, Volume 8, Issue 1, 10 July 2014, Pages 242–255 
Copyright © 2014 Xiaoying Wu, Donna Romero, Wojciech I. Swiatek, Irene 
Dorweiler, Chintan K. Kikani, Hana Sabic, Ben S. Zweifel, John McKearn, Jeremy 
T. Blitzer, G. Allen Nickols, Jared Rutter 
This article is published under the terms of the Creative Commons Attribution-







PAS Kinase Drives Lipogenesis
through SREBP-1 Maturation
XiaoyingWu,1 Donna Romero,2 Wojciech I. Swiatek,1 Irene Dorweiler,1,3 Chintan K. Kikani,1 Hana Sabic,1 Ben S. Zweifel,2
John McKearn,2 Jeremy T. Blitzer,2 G. Allen Nickols,2,4 and Jared Rutter1,*
1Department of Biochemistry, University of Utah School of Medicine, 15 N. Medical Drive East, Salt Lake City, UT 84112-5650, USA
2Synergenics, 1700 Owens Street, Suite 515, San Francisco, CA 94158, USA
3Present address: Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA
4Present address: Mallinckrodt, LLC, 675 McDonnell Boulevard, St. Louis, MO 63042, USA
*Correspondence: rutter@biochem.utah.edu
http://dx.doi.org/10.1016/j.celrep.2014.06.006
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
SUMMARY
Elevated hepatic synthesis of fatty acids and triglyc-
erides, driven by hyperactivation of the SREBP-1c
transcription factor, has been implicated as a causal
feature of metabolic syndrome. SREBP-1c activation
requires the proteolytic maturation of the endo-
plasmic-reticulum-bound precursor to the active,
nuclear transcription factor, which is stimulated by
feeding and insulin signaling. Here, we show that
feeding and insulin stimulate the hepatic expression
of PASK. We also demonstrate, using genetic and
pharmacological approaches, that PASK is required
for the proteolytic maturation of SREBP-1c in
cultured cells and in the mouse and rat liver. Inhibi-
tion of PASK improves lipid and glucose metabolism
in dietary animal models of obesity and dyslipidemia.
Administration of a PASK inhibitor decreases hepatic
expression of lipogenic SREBP-1c target genes, de-
creases serum triglycerides, and partially reverses
insulin resistance. While the signaling network that
controls SREBP-1c activation is complex, we pro-
pose that PASK is an important componentwith ther-
apeutic potential.
INTRODUCTION
Excessive synthesis and storage of lipids is a prominent feature
of the current epidemic of metabolic disorders, including
obesity, diabetes, and their comorbidities. Upon feeding, fatty
acids and triglycerides are synthesized primarily in the liver and
adipose tissue in response to insulin signaling, and then are
either stored locally or exported to other tissues for use in ATP
production. The Sterol Regulatory Element Binding Protein
(SREBP-1c) transcription factor is a principal regulator of lipo-
genesis in these two tissues (Horton et al., 2002; Rosen et al.,
2000). Upon activation, SREBP-1c stimulates expression of the
entire enzymatic pathway that converts acetate to fatty acids
and their esterification to triacylglycerol (TAG) (Horton et al.,
2003). Hyperactivation of SREBP-1c has been implicated in
promoting pathological fat synthesis and driving features of
metabolic syndrome, including hepatic lipid accumulation (or
steatosis), dyslipidemia, and insulin resistance (Brown andGold-
stein, 2008).
Although it is often pathological in modern humans, SREBP-
1c activation in response to feeding is a normal physiological
response that enables the storage of excess energy in the sta-
ble and compact TAG form. SREBP-1c activation by feeding
occurs predominantly in response to insulin, which acts at mul-
tiple regulatory steps. Transcription of the SREBP-1c mRNA is
strongly induced by insulin via a mechanism involving the LXR
transcription factor (Chen et al., 2004; DeBose-Boyd et al.,
2001; Repa et al., 2000; Schultz et al., 2000; Yoshikawa
et al., 2001) and SREBP-1c autoregulation (Amemiya-Kudo
et al., 2000; Chen et al., 2004). Insulin also acts, through
GSK-3b inhibition and potentially through Lipin1 phosphoryla-
tion, to extend the otherwise very short half-life of active
SREBP-1c (Harris et al., 2007; Pe´terfy et al., 2010; Peterson
et al., 2011; Sundqvist et al., 2005). One of the most important
mechanisms underlying SREBP-1c activation by insulin
signaling, however, is the proteolytic maturation of the endo-
plasmic reticulum (ER) membrane-embedded SREBP-1c
precursor into the active and nuclear mature SREBP-1c tran-
scription factor (Hegarty et al., 2005).
Analogous to what has been described for its better-charac-
terized paralog, SREBP-2, maturation of SREBP-1c is thought
to occur through the regulated translocation of the precursor
to the Golgi, where it is cleaved sequentially by two proteases,
liberating the mature form from its two transmembrane seg-
ments (Horton et al., 2002; Raghow et al., 2008). The regulatory
pathway linking insulin and SREBP-1c maturation is incom-
pletely understood, but has been shown to require the canonical
PI3K/Akt pathway (Krycer et al., 2010; Yellaturu et al., 2009a).
More recently, evidence has shown that insulin-responsive
SREBP-1c activation also requires the mechanistic Target of
Rapamycin Complex 1 (mTORC1) (Du¨vel et al., 2010; Li et al.,
2010; Porstmann et al., 2008). Although part of the effect of in-
sulin/Akt on SREBP-1c maturation appears to depend on the
regulation of INSIG2 gene expression (Yecies et al., 2011; Yell-
aturu et al., 2009b), the mechanism(s) underlying Akt/mTORC1’s
effect on SREBP-1c proteolytic maturation have not been
identified.
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PAS kinase (PASK) is an evolutionarily conserved serine/thre-
onine kinase, and we previously proposed that it plays an impor-
tant role as a nutrient-responsive metabolic regulator (Hao and
Rutter, 2008). Mice lacking the PASK gene (Pask!/!) exhibit
a number of tissue-specific metabolic abnormalities, but the
most profound phenotype observed to date is decreased sus-
ceptibility to hepatic lipid infiltration in animals challenged with
a high-fat diet (HFD) (Hao et al., 2007). Hepatic steatosis is
now recognized to be a common and devastating component
of metabolic syndrome (Cohen et al., 2011). However, the mole-
cularmechanisms underlying hepatic steatosis are unknown and
no therapies are currently approved for its treatment. Given the
profound Pask!/! phenotype, the importance of this process in
human disease, and the potential to discover new therapeutic
targets, we sought to identify the mechanism whereby PASK
regulates hepatic lipid metabolism.
RESULTS
PASK Stimulates Hepatic Lipogenesis by Activating
SREBP-1c
Since Pask!/! mice are protected from HFD-induced hepatic
steatosis, we initially compared the hepatic transcriptional pro-
files of lipogenic genes from Pask!/! and wild-type (WT) mice
in both fasted and fed states. The expression levels of the genes
encoding glycerol-3-phosphate acyltransferase (Gpat1), fatty
acid synthase (Fasn), and acetyl-coA carboxylase (Acc1) were
all similarly low in the fasted state in WT and Pask!/! livers (Fig-
ures 1A–1C). Although expression of these genes increased sub-
stantially in WT mice upon feeding, this induction was blunted in
Pask!/! mice (Figures 1A–1C). This feeding-dependent effect
led us to test the expression of these same genes in fasted
and fed mice that were maintained on a normal chow diet
(NCD). As with the HFD, the expression levels of the lipogenic
genes were similar in WT and Pask!/! mice in the fasted state.
Refeeding for 6 or 8 hr, however, significantly increased the
expression of Gpat1, Fasn, and Acc1 in WT liver, and this in-
crease was absent or blunted in Pask!/! mice (Figures 1D–1F).
We previously observed that PASK activity was nutrient
responsive in cultured cells. This led us to hypothesize that
PASK expression or activity might also be stimulated in the liver
upon feeding, which might then be required for NCD-induced
lipogenic gene expression. We therefore measured the hepatic
Pask mRNA levels in fasted and fed mice. HFD-fed WT mice
showed an increase inPask expression upon feeding (Figure 1G).
An even larger increase was observed in NCD-fed animals upon
2 hr of feeding following a fast (Figure 1H). Interestingly, by 6 hr of
feeding, the Pask mRNA abundance had returned to the fasted
level. This acute hepatic induction of Pask by feeding is likely
to be a cell-autonomous response to insulin, as we observed
induction of Pask mRNA by insulin in WT primary hepatocytes
(Figure 1I).
To further investigate the mechanisms whereby PASK defi-
ciency led to reduced expression of lipogenic genes, we em-
ployed HepG2 human hepatoma cells treated with insulin, which
is a major hormonal mediator of the response of lipogenic gene
expression to feeding. PASK knockdown by three different small
interfering RNAs (siRNAs; denoted as siA, siB, and siC) in HepG2
cells (Figure 2A) caused decreased expression of GPAT1 and
SCD1 upon insulin treatment (Figure 2B). Unlike the liver, how-
ever, HepG2 cells seem to have a basal level of lipogenic gene
expression that is PASK dependent. In the absence of insulin,
PASK knockdown caused decreased expression of GPAT1
and SCD1 in HepG2 cells (Figure S1A). The fact that acute
PASK knockdown in HepG2 cells recapitulates the regulation
of gene expression observed in vivo in Pask!/! liver suggests a
direct role for PASK in regulating lipogenesis.
To determine whether this change in mRNA abundance is due
to transcriptional control, we examined the effects of PASK
knockdown on luciferase activity from a reporter gene driven
by the promoter of either GPAT1 (Yoshida et al., 2009) or
SCD1 (Bene´ et al., 2001). As shown in Figures S1B and S1C,
PASK knockdown decreased the activity of both the GPAT1
and SCD1 promoters. Because SREBP-1c is one of the major
feeding- and insulin-responsive regulators of GPAT1, SCD1,
and the other components of the fatty acid and TAG biosynthetic
pathway, we analyzed the effects ofPASK knockdown on a lucif-
erase reporter gene containing isolated SREBP-binding sites
(Dooley et al., 1998). PASK knockdown caused a modest reduc-
tion in SREBP activity in serum-starved conditions, which
became more pronounced upon insulin treatment (Figure 2C).
One potential explanation for the loss of basal and insulin-stim-
ulated SREBP-1 activation upon PASK knockdown is that the
Akt/mTORC1 pathway, which is required for SREBP-1 activa-
tion, is impaired by PASK knockdown. However, the phosphor-
ylation states of Akt and S6K (indicative of Akt and mTORC1
activity, respectively) were both unchanged by PASK knock-
down (Figure 2D), demonstrating that the effects of PASK on
SREBP-1 activation occur without effects on Akt and mTORC1
activity. Over many independent experiments, PASK knock-
down with each of these three different siRNAs caused a sig-
nificant impairment in the fold-induction of SREBP activity by
insulin (siA: n = 15, p = 0.003; siB: n = 16, p < 0.0001; siC: n =
9, p = 0.01). Taken together, these data support a model wherein
SREBP-1c is a major mediator of the transcriptional effects of
PASK on the regulation of lipid biosynthesis, and PASK is
required for the full effect of insulin on SREBP-1c induction.
PASK Promotes SREBP-1 Maturation
SREBP-1c is profoundly regulated by insulin atmultiple levels, as
described above. Given the requirement of PASK for the normal
regulation of SREBP-1c, we first assessed whether it is also
required for its proteolytic maturation. We examined this directly
by monitoring the levels of the precursor and mature forms of
SREBP-1c. We also examined the maturation of SREBP-1a,
which is derived from the same gene as SREBP-1c but is the
product of an alternative promoter (Hua et al., 1995). Treatment
of cells with either one of two PASK-specific siRNAs (siA and
siB), but not the control siRNA, blunted the insulin-responsive
maturation of SREBP-1a and SREBP-1c (Figures 3A and S2A).
As before, PASK knockdown impaired SREBP-1 processing,
but had no effect on Akt or S6K phosphorylation (Figures 3A
and S2A). The insulin-responsive proteolytic maturation of
SREBP-1c is also observed upon feeding in rodent liver. In WT
mice maintained on an NCD, we observed a significant increase
in the abundance of mature SREBP-1c in the fed state relative to




the fasted state (Figure 3B). This induction was severely blunted
in Pask!/! mice (Figure 3B). Feeding-induced maturation of
SREBP-1c was also observed in WT mice maintained on an
HFD, but was essentially absent in Pask!/! mice (Figure 3C).
The INSIG proteins are negative regulators of SREBP-1
maturation and are regulated at many levels, including transcrip-
tion and mRNA stability (Gong et al., 2006; Yabe et al., 2002,
2003; Yang et al., 2002; Yellaturu et al., 2009b). Alterations
in the expression of Insig2a have been specifically implicated
in mediating the effects of insulin on SREBP-1c processing in
hepatic tissue (Yabe et al., 2003; Yecies et al., 2011; Yellaturu
et al., 2009b). However, it appears that the effects of PASK
knockdown on SREBP-1c maturation are not due to altered
INSIG2 expression, as this gene is not induced in HepG2 cells
upon PASK knockdown (Figure 3D). In fact, INSIG2 expression
actually is decreased by two out of three PASK-targeted
siRNAs, perhaps as a compensatory mechanism that the cell
employs to attempt to restore SREBP-1c maturation. We
measured the Insig1, Insig2a and Insig2b mRNAs in WT and
Pask!/! liver under fed and fasted conditions in mice maintained
on either the NCD or HFD. Again, under no condition did we
observe an increase in Insig2a expression (Figures 3E and 3F).
Figure 1. PASK Is Feeding Induced and Is Required for Normal Feeding-Dependent Induction of Lipogenic Gene Expression.
(A–H) WT and Pask!/! (KO) mice on the C57/BL6J background were maintained on a 60% HFD (A–C and G) for 8 weeks (n R 4) or an NCD (D–F and H) for
12 weeks (n = 3). Before harvesting, mice were fasted for 24 hr or fasted for 24 hr and refed either an HFD for 12 hr (A–C and G) or an NCD for the indicated times
(D–F and H). Livers were harvested and themRNA levels of the indicated geneswere measured by quantitative RT-PCR (qRT-PCR) and normalized toCyclophilin
A mRNA. Data shown are the average ± SEM, with the ‘‘WT fasted’’ value set as one.
(I) Rat primary hepatocytes were serum starved overnight and incubated with 25 nM insulin for the indicated times. PaskmRNA was measured by qRT-PCR and
normalized to r36B4. Data shown are the average of n = 3 ± SEM. The value of the 0 hr group was set as one.
See also Tables S1 and S2.




We also did not observe an increase in expression of the other
INSIG isoforms, Insig1 and Insig2b, in Pask!/! mice (Figures
S2B and S2C). We therefore conclude that PASK promotes
SREBP-1 maturation, but does so independently of effects on
INSIG gene expression.
We also addressed whether PASK might regulate the stability
or transcriptional activation potential of mature, nuclear
SREBP-1 (other known mechanisms of SREBP-1 control). We
expressed a truncated form of SREBP-1a, or GFP as a control,
and asked whether PASK knockdown had any effect on SRE-
driven luciferase activity. As shown in Figure 3G, PASK knock-
down with siB in GFP-control cells led to decreased luciferase
activity in both the presence and absence of insulin. Expression
of the mature SREBP-1a, however, caused luciferase activity to
become completely insensitive to PASK knockdown (Figure 3G).
We were concerned that expression of this ectopic transcription
factor might have overwhelmed the PASK regulatory system and
the PASK insensitivity was due to an overexpression artifact.
Therefore, we expressed the full-length, precursor SREBP-1a
and found that PASK knockdown retained the ability to suppress
luciferase activity (Figure 3G). To achieve a similar transcriptional
response, we expressed much more full-length SREBP-1a,
which requires processing for activation. In spite of this, the
full-length SREBP-1a was regulated by PASK, whereas
the mature form of SREBP-1a was not. We thus conclude that
the activity of the nuclear, mature form is resistant to PASK
knockdown. PASK knockdown with siA, which is more effective
at silencing PASK and decreasing SREBP-1 activity (Figure 2),
followed the same pattern, although PASK knockdown still
caused a small but significant decrease in SREBP activity even
when the mature SREBP-1a was expressed (Figure S2D).
This was likely due to endogenous SREBP-1, whose activity
remained PASK dependent. As before, the activity of over-
expressed full-length, precursor SREBP-1a was PASK depen-
dent. The loss of SREBP-1 activity upon PASK knockdown
again occurred in the absence of any effect on insulin or
mTORC1 signaling (Figures 3G and S2D). We initially attempted
the above experiment with SREBP-1c, which has much weaker
transcriptional activation potential than SREBP-1a (Shimano
et al., 1997a), but we were unable to express enough full-length
precursor SREBP-1c to achieve comparable luciferase activity.
This technical issue prevented a rigorous interpretation of the
analogous experiment with SREBP-1c.
Finally, we sought to address whether the transcriptional
control of SREBP-1c might depend upon PASK. This is a difficult
question to answer, however, because SREBP-1c stimulates the
expression of its own promoter (Amemiya-Kudo et al., 2000;
Chen et al., 2004). Therefore, posttranscriptional effects on
Figure 2. PASK Is Required for Full SREBP-1 Activity
(A) HepG2 cells were treated with scrambled or PASK-specific siRNA (siA, siB, or siC) and subjected to immunoblot for PASK.
(B)PASK-silenced HepG2 cells were serum starved overnight and stimulatedwith 100 nM insulin for 6 hr. ThemRNA levels of the indicated genes weremeasured
by qRT-PCR and normalized to Tubulin mRNA levels. Data shown are the average of n = 3 ± SEM, with the Scr value set as one.
(C) PASK-silenced HepG2 cells were transfected with SRE-Luc reporter, serum starved overnight, and stimulated with 100 nM insulin for 6 hr as indicated.
Firefly and Renilla luciferase were assayed using the Dual-Reporter Luciferase Assay System. Data shown are the average of n = 3 ± SD, with the ‘‘scr!ins’’ value
set as one.
(D) Following the luciferase assay, cell lysates from (C) were subjected to immunoblot to determine the phosphorylation state and abundance of the indicated
proteins.
See also Figure S1.




Figure 3. PASK Promotes SREBP-1 Maturation
(A) PASK-silenced HepG2 cells expressing GFP, 3xFlag-tagged precursor SREBP-1a, or SREBP-1c were serum starved overnight and stimulated with 100 nM
insulin for 6 hr as indicated. Whole-cell lysates and nuclear extracts were subjected to immunoblot to determine the phosphorylation state and abundance of the
indicated proteins.
(B and C) Livers were harvested fromWT or Pask!/! (KO) mice maintained on an NCD (B) or HFD (C) as described in Figure 1, except that mice were refed for 8 hr
(B) or 6 hr (C). Whole-liver lysates and nuclear extracts were subjected to immunoblot to determine the abundance of the indicated proteins.
(legend continued on next page)




SREBP-1c activity will indirectly result in alterations to the
SREBP-1c mRNA level. As expected, we observed that
the SREBP-1c mRNA was decreased in Pask!/! liver (Table
S1) in parallel with the decrease in SREBP-1c target genes
described above (Figure 1). Inhibition of PASK caused a modest
reduction in the activity of the mSREBP-1c promoter as deter-
mined using a luciferase reporter assay in rat primary hepato-
cytes stimulated with insulin (Figure S2E). This effect of PASK
on promoter activity was dependent on SREBP-1 autoregula-
tion, however, as a promoter in which the SREBP-binding site
had been mutated showed no response to PASK inhibition (Fig-
ure S2E). We also observed amodest decrease in the level of the
SREBP-1a mRNA (Table S1), but this is unlikely to be a major
contributor to the expression of lipogenic genes in the liver
because it is expressed at a much lower level than SREBP-1c
(Shimomura et al., 1997). We observed no consistent alteration
in the expression of SREBP-2 or its target genes in Pask!/!
mice maintained on either the NCD or HFD (Tables S1 and S2).
Taken together, these experiments suggest that in the absence
of transcriptional control, PASK regulates the posttranslational
maturation of SREBP-1 in response to insulin. However, we
cannot exclude the possibility that PASK might also regulate
SREBP-1c transcriptionally.
Pharmacological Inhibition of PASK Leads to Decreased
SREBP-1 Activity
To facilitate the assessment of the importance of PASK for regu-
lating SREBP-1c activity and lipid homeostasis in vivo, we devel-
oped a series of PASK inhibitors. Among them, we selected for
further study two highly selective and potent inhibitors: BioE-
1115 and BioE-1197 (Figure 4A). To assess their in vitro speci-
ficity, we measured the activity of PASK and 50 other protein
kinases, selected to represent the breadth of the human kinase
family, in the presence of BioE-1115 or BioE-1197. As shown
in Figure 4B, BioE-1115 specifically inhibits PASK, with an IC50
of "4 nM. Second to PASK, casein kinase 2a was the kinase
most potently inhibited by BioE-1115, having an IC50 of
"10 mM. This is interesting because of the unexpected structural
similarities between the kinase domains of PASK and casein
kinase 2 (Kikani et al., 2010). In spite of this similarity, however,
BioE-1115 was roughly 2,500-fold more potent as an inhibitor
of PASK than of casein kinase 2a2 (Figure 4B). BioE-1197
showed similar specificity for PASK versus the same 50 protein
kinases. As shown in Figure S3A, even when we used an
extremely high concentration of BioE-1197 (100 mM), the
majority of the 50 kinases were either unaffected or only
modestly inhibited. PASK, however, was essentially completely
inactivated and eight other kinases were also substantially in-
hibited. In full dose-response inhibition curves for these nine
BioE-1197-sensitive kinases, all but two were inhibited poorly,
with an IC50 of >50 mM (Figure S3B). Similar to what we observed
with BioE-1115, casein kinase 2a was inhibited by BioE-1197,
but with a "1,000-fold higher IC50 compared with PASK (Fig-
ure S3B). For subsequent use as a control, we also synthesized
an enantiomer of BioE-1197, which was"100-fold less potent at
inhibiting PASK in vitro (IC50 = 870 nM; Figure 4C).
We next examined the efficacy of BioE-1115, BioE-1197, and
BioE-1428 for PASK inhibition in cultured cells. We tested this by
virtue of the ability of PASK to autophosphorylate at Thr-307,
which we have demonstrated to be solely dependent upon
PASK activity (Figure S3C). In the presence of either BioE-1115
or BioE-1197, we observed a dose-dependent loss of PASK
phosphorylation, with an IC50 of"1 mM (Figure 4D). As expected,
the enantiomer BioE-1428 was less effective at PASK inhibition
in cells, with an IC50 of >10 mM (Figure 4D).
Having validated that BioE-1115 and BioE-1197 are potent
and specific inhibitors of PASK, we were then able to use them
to probe the acute effects of PASK inhibition. Specifically, we
sought to determine whether pharmacological PASK inhibition,
like PASK knockdown and PASK deletion, leads to impaired
SREBP-1 activity. We measured SRE-driven luciferase activity
in the presence of varying concentrations of BioE-1115 and
BioE-1197. We observed a significant reduction in SREBP acti-
vity at all concentrations above 10 mM for BioE-1115 and 3 mM
for BioE-1197 (Figure 5A), without any observable effects on
cell morphology or growth rate. This effect is likely to be specific
for PASK inhibition, because treatment of cells with BioE-1428
caused only a modest reduction of SREBP activity even at the
highest concentration tested, 50 mM (Figure S3D). As with
PASK knockdown, neither compound impaired the phosphory-
lation of Akt or S6K in response to insulin (Figures 5B and
S3E), demonstrating again that the loss of SREBP-1 activity is
not due to a loss of canonical insulin signaling.
If BioE-1115 and BioE-1197 suppress SREBP-1 activity
through inhibition of PASK, they should act by blocking
SREBP-1 proteolytic activation, as was observed with PASK
knockdown in cells and in the liver of Pask!/! mice. Both BioE-
1115 and BioE-1197 suppressed SREBP-1c maturation, as
evidenced by a decrease in the mature/precursor SREBP-1c
ratio, at 30 and 50 mM concentrations (Figures 5C and S3F). In
contrast, BioE-1428 had no effect at 30 mM and the effect at
50 mM was weaker than observed with BioE-1197 (Figure S3F).
When quantified over five independent experiments, BioE-
1197 was significantly more efficacious at suppressing
SREBP-1c maturation than BioE-1428 (Figure S3G). In sum-
mary, both PASK knockdown and pharmacological inhibition
led to impaired SREBP-1 activity, and both manipulations
impacted the maturation step. These complementary data
support the hypothesis that PASK is required for the normal
maturation and activation of SREBP-1.
(D) HepG2 cells were treated and human INSIG2mRNA levels were analyzed as in Figure 2B. Data shown are the average of n = 3 ± SEM, with the Scr value set
as one.
(E and F) Mouse Insig2a mRNA levels in livers of mice (from B and C) fed an NCD (E) or HFD (F) were measured as described in Figure 1. Data shown are the
average of n = 3 ± SEM, with the ‘‘WT fasted’’ value set as one.
(G) Left: SRE-Luc activity was measured in PASK-silenced HepG2 cells expressing GFP or mature or precursor SREBP-1a along with SRE-Luc. Right: following
the luciferase assay, cell lysates were subjected to immunoblot to determine the phosphorylation state and abundance of the indicated proteins.
See also Figure S2.




We next tested whether PASK inhibition would lead to a
decrease in the synthesis of fatty acids and triglycerides, as
would be predicted based on the impairment in SREBP-1c
activity. We measured the incorporation of 14C from 14C-acetate
into lipid soluble material, which is primarily triglyceride under
these conditions. Treatment with 10 mM BioE-1197 caused a
!60% decrease in 14C incorporation into lipids (Figure 5D),
suggesting that the impaired SREBP-1 activity is manifest at
the level of lipogenesis.
Rat primary hepatocytes have been used extensively in
studies of insulin-responsive SREBP-1c activation and lipo-
genesis. We previously observed that PASK gene expression
was stimulated by insulin (Figure 1I). Therefore, we explored
whether PASK inhibition would have any effect on the insulin-
responsive expression of SREBP-1c target genes in these cells.
Primary hepatocytes were isolated, plated, pretreated with
DMSO or BioE-1197 for 16 hr, and then stimulated with either
insulin or vehicle over a 12 hr time course. Insulin caused a sig-
nificant increase in the mRNAs encoding fatty acid synthase and
glucokinase (Fasn and Gck, respectively; Figures 5E and 5F).
This increase was either blunted or abolished by the PASK inhib-
itor. In these cells, BioE-1197 caused a significant decrease in
the mRNA encoding SREBP-1c under both basal and insulin-
stimulated conditions (Figure 5G). Finally, we measured the
incorporation of 14C from 14C-acetate into lipids. Insulin caused
a significant increase in lipogenesis in vehicle-treated hepato-
cytes, which was completely abolished by treatment with
BioE-1197 (Figure 5H).
PASK Inhibition Reduces SREBP-1c Activity and
Hypertriglyceridemia in Rodents
We previously observed that PASK deficiency in mice leads to
protection against many of the pathological effects of an HFD
(Hao et al., 2007). Most prominently, in the previous study we
Figure 4. BioE-1115 and BioE-1197 are PASK-Specific Inhibitors
(A) Chemical structures of BioE-1115, BioE-1197, and BioE-1428.
(B) The activity of the indicated kinases was measured in the presence of either vehicle or BioE-1115, and IC50 values were measured.
(C) Purified PASK protein kinase activity was assayed as in (B) in the presence of the indicated concentrations of BioE-1197, BioE-1428, or BioE-1115, and the
percentage of vehicle-treated activity was determined as indicated.
(D) HEK293 cells expressing a Flag-tagged PASK protein were treated with the indicated concentrations of BioE-1115, BioE-1197, or BioE-1428. PASK activity
was analyzed by ELISA with both phospho-Akt substrate antibody and pan-PASK antibody. The quantitated phospho/total PASK signal is plotted ± SEM.
See also Figure S3.




found that Pask!/! mice were protected from the severe diet-
induced hepatic steatosis observed in WT mice. This lipid
phenotype was accompanied by a decrease in the expression
of the lipogenic program driven by SREBP-1c (Figure 1).
Because we conducted these studies using a constitutively
deleted allele of PASK, however, we were concerned that this
phenotype might be due to adaptation or a developmental
abnormality. Therefore, we initiated studies to address the
effects of acute inhibition of PASK in adult animal models of
metabolic disease. These studies were conducted with BioE-
1115 due to the more favorable in vivo pharmacological and
pharmacokinetic properties of this PASK inhibitor relative to
BioE-1197 (Figure S4A).
WT Sprague-Dawley (SD) rats at 12 weeks of age were fed for
2 weeks with either an NCD or a high-fructose diet (HFrD), which
is known to promote dyslipidemia and insulin resistance (Hwang
et al., 1987). Those fed the HFrD were then orally dosed with
vehicle or a range of doses of BioE-1115 once a day for
1 week. Following this 1-week treatment, we harvested livers
from these rats after they were refed, and examined the mRNA
levels of SREBP-1c target genes. As expected, the SREBP-1c
target genes were upregulated in animals fed the HFrD relative
to control (Figures 6A and S4B–S4D). Among the HFrD group,
rats treated with either 1 or 3 mg BioE-1115 per kilogram of
body weight (mg/kg) showed no difference from vehicle-treated
rats. Those treatedwith 10, 30, and100mg/kg, however, showed
a dose-dependent suppression of the expression ofGpat1, Fasn
(Figure 6A), and all other SREBP-1c target genes analyzed (Fig-
ures S4B–S4D). SREBP-1 maturation in the liver was also sup-
pressed in BioE-1115-treated rats at these three doses (Fig-
ure 6B), which is consistent with what we observed in Pask!/!
mouse liver. However, the SREBP-2 target genes did not follow
this pattern consistently (Figures S4E–S4I). In fact, HMG-CoA
synthase1andSREBP-2 itself both followed theopposite pattern
(Figures S4E and S4J), being induced in a dose-dependent
manner by BioE-1115. This is particularly intriguing given that
mice lacking SREBP-1 frequently die in utero, but those that sur-
vive exhibit elevated expression ofSREBP-2 and its target genes,
implying some sort of compensatory mechanism between the
two transcription factors (Shimano et al., 1997b). One SREBP-2
target gene, that encoding HMG-CoA reductase, was signifi-
cantly decreased in BioE-1197-treated animals (Figure S4F).
Interestingly, this is the one SREBP-2 target gene that was also
significantly underexpressed in Pask!/! mice (Table S2). Both
SREBP-1c and SREBP-1a mRNA were modestly decreased at
the highest doses of BioE-1115 (Figures S4K and S4L).
In addition to the marked change in SREBP-1c target gene
expression, we also observed a reversal of the dyslipidemic
features associated with an HFrD, as BioE-1115 treatment
caused a decrease in hepatic TAG (Figure 6C). Similarly, serum
TAG was also decreased in a dose-dependent manner by
BioE-1115 administration (Figure 6D), whereas serum choles-
terol was basically unaffected (Figure 6E). Due to the normali-
zation of triglyceride concentrations, we speculated that
BioE-1115 might have salutary effects on glucose homeostasis
as well. Indeed, the PASK inhibitor caused a significant decrease
in serum glucose (Figure 6F). This drop in glucose levels was
almost certainly a consequence of increased insulin sensitivity
rather than increased insulin secretion, as serum insulin levels
were slightly lower (rather than higher) in drug-treated animals
(Figure 6G). A calculated measure of insulin resistance, termed
homeostasis model assessment-estimated insulin resistance
(HOMA-IR), was decreased in a dose-dependent manner by
BioE-1115 administration (Figure 6H). Neither dose of BioE-
1115 caused a significant change in either liver weight or body
weight (Figures 6I and 6J), suggesting that the effects on lipid
and glucose homeostasis were not due to overt toxicity.
We next performed a study of similar design except that the
HFrD-fed rats were treated for 90 days with either vehicle or
BioE-1115. The effect on SREBP-1c target gene expression
was enhanced with the longer treatment time. At 3 mg/kg
BioE-1115, expression of both Fasn and Acc1 was significantly
suppressed by PASK inhibition, and at 10, 30, and 100 mg/kg,
expression of these genes was restored to that in NCD-fed
animals (Figure S5A). The effect on SREBP-1c activity appears
to be specific for the liver, as there were no significant differ-
ences in the expression of SREBP-1c or its target genes in
abdominal fat (Figure S6A) or in gastrocnemius muscle (Fig-
ure S6B) upon BioE-1115 treatment. After 90 days of treatment
and at the interim time point of 45 days, we observed a signifi-
cant dose-responsive decrease in serum triglycerides (Figures
S5B and S5C). As in the shorter dosing period, BioE-1115
decreased serum glucose levels as measured by glycated
hemoglobin (HbA1c), which is a measure of chronic glycemia
(Figures S5D and S5E). After both 51 and 90 days of dosing,
therewas no drug-dependent difference in bodyweight between
any of the vehicle or treatment groups (Figures S5F and S5G).
DISCUSSION
The regulation of SREBP-1c is complex in terms of both the
regulatory stimuli involved and how these stimuli impinge upon
SREBP-1c activity (Raghow et al., 2008). The most widely stud-
ied and understood stimulus that promotes SREBP-1c activation
is insulin, and various components of its downstream signaling
pathway, including Akt and mTOR, have been implicated (Jeon
and Osborne, 2012). These related mechanisms combine to
elicit a profound activation of SREBP-1c in response to feeding.
We show herein that PASK is transcriptionally induced by
feeding in vivo in the liver and is also induced in a cell-autono-
mous manner by insulin in primary hepatocytes. This induction
appears to be related to SREBP-1c activation, as PASK is
required for normal feeding and insulin-responsive SREBP-1c
activity. Inhibition of PASK also impairs insulin-responsive lipid
biosynthesis, which is driven by SREBP-1c. We demonstrated
this requirement for PASK in SREBP-1c activation in four model
systems and by using three distinct modalities to block PASK
activity. SREBP-1c-driven transcription is impaired by genetic
deletion of PASK in mice fed either an NCD or HFD, pharmaco-
logical inhibition and siRNA-mediated knockdown in cultured
HepG2 cells, and pharmacological inhibition in both rat primary
hepatocytes and HFrD-fed rats. Not only do these disparate
manipulations cause the same physiological effect, they also
appear to act via the same biochemical mechanism. This pro-
vides a compelling argument that PASK is an important regulator
of SREBP-1c activation.




Figure 5. Pharmacological Inhibition of PASK Suppresses SREBP-1 Activation
(A) SRE-Luc activity wasmeasured in HepG2 cells treated overnight with vehicle or the indicated doses of BioE-1115 or BioE-1197 followed by 100 nM insulin for
6 hr. Data are normalized to vehicle-treated samples and shown as the average of n = 3 ± SD.
(B) HepG2 cells were treated as in (A). Cell lysates were subjected to immunoblot to determine the phosphorylation state and abundance of the indicated proteins.
(C) HepG2 cells were infected as in Figure 3A and treated with PASK inhibitors and insulin as in (A). Whole-cell lysates and nuclear extracts were subjected to
immunoblot to determine the abundance of indicated proteins.
(D) 14C-acetate incorporation into lipid was measured in BioE-1197-treated HepG2 cells and normalized to the total protein in the lysate. Data shown are the
average of n = 3 ± SD.
(legend continued on next page)




Insulin regulates SREBP-1c at almost every level of its expres-
sion and stability. Expression of the SREBF-1 gene is robustly
stimulated by insulin (Raghow et al., 2008). The precursor
SREBP-1c protein is synthesized in a latent, inactive form that
is embedded in the ER membrane. Upon insulin stimulation,
SREBP-1c translocates to the Golgi, where the protein en-
counters two proteases that cleave it to release an N-terminal
fragment that is competent to bind DNA and activate gene
expression. SREBP-1c maturation is controlled by two asso-
ciated proteins, SCAP and INSIG (Raghow et al., 2008). Insulin
increases the transcriptional activation potential of mature
SREBP-1c (Dif et al., 2006; Kotzka et al., 1998). Finally, insulin
also impedes the otherwise rapid degradation of the mature,
nuclear form of SREBP-1c (Raghow et al., 2008). In total, this
multiplicity of regulatory processes enables a robust induction
of SREBP-1c by insulin that is both rapid and sustained.
The principal regulatory point at which PASK acts appears
to be the proteolytic maturation of the precursor to mature
SREBP-1c. This is best evidenced by the decrease in the mature
form and increase in the precursor form observed in cells sub-
jected to PASK knockdown or inhibition. A specific decrease in
themature form is also observed in Pask!/!mice in the fed state.
We cannot eliminate the possibility, however, that PASK might
also regulate the synthesis or stability of the SREBF-1 mRNA.
We observed that Pask!/! liver, PASK knockdown HepG2 cells,
and primary hepatocytes with PASK inhibition all had lower
SREBP-1c mRNA levels than the controls. However, this could
be explained by the fact that SREBP-1c positively regulates its
own gene expression (Amemiya-Kudo et al., 2000; Chen et al.,
2004). If the loss of PASK impairs the proteolytic activation of
SREBP-1c, this would secondarily lead to a decrease in the
SREBP-1c mRNA level. In fact, we found that PASK inhibition
decreased the activity of a luciferase reporter driven by the
SREBP-1c promoter in response to insulin, but this effect was
completely eliminated when the autoregulatory SREBP-binding
site within the promoter was mutated. It remains possible that
PASK acts at other steps to regulate SREBP-1c activity; never-
theless, our data do show that normal insulin-responsive matu-
ration requires PASK.
The mechanisms whereby insulin signaling promotes the
proteolytic activation of SREBP-1 are still incompletely under-
stood. It has been observed that Akt, in response to insulin
signaling, leads to the phosphorylation of SREBP-1c in amanner
that correlates with activation (Yellaturu et al., 2009a). Although
the functional significance of this SREBP-1c phosphorylation
has not been established yet, it is possible that PASK might
directly phosphorylate SREBP-1c to promote its maturation.
More recent work has shown that insulin signals through both
mTORC1-dependent and mTORC1-independent pathways to
promote SREBP-1 activation (Wan et al., 2011; Yecies et al.,
2011). The latter involves the regulation of INSIG2a, which is a
negative regulator of SREBP-1 (Yecies et al., 2011; Yellaturu
et al., 2009b). PASK does not appear to act through this mech-
anism, since INSIG2 mRNA is not higher upon PASK knock-
down, as would be expected if this were the explanation for
impaired SREBP-1 processing. In fact, the INSIG2 mRNA is
lower upon PASK knockdown, perhaps as a compensatory
effect in response to impaired SREBP-1 activation.
The proteins and mechanisms that connect mTORC1 activa-
tion with stimulation of SREBP-1 processing are currently un-
known. Our data demonstrate that PASK is not required for Akt
or mTORC1 activation in response to insulin signaling, which
leads us to conclude that PASK acts either downstream of
mTORC1 or in a parallel pathway to promote SREBP-1 acti-
vation. The precise placement of PASK in this signaling network
and definition of the mechanisms that connect the nodes of this
network await further studies.
Not only did administration of the PASK inhibitor cause pro-
found decreases in the hepatic expression of SREBP-1c target
genes and the generation of mature SREBP-1, it also impacted
hepatic and systemic metabolic parameters. Both hepatic and
serum triglycerides were normalized, which might be expected
based on the suppression of lipogenic gene expression in the
liver. In addition, we observed a significant decrease in serum
glucose in HFrD-fed rats treated with the PASK inhibitor for
7 days, and in HbA1c in rats treated for either 45 or 90 days. In
conjunctionwith themodestdecrease in serum insulin, this is sug-
gestive of enhanced insulin sensitivity in inhibitor-treated animals.
A pathological vicious cycle has been described wherein the
hypoglycemic effects of insulin are blunted, but insulin maintains
the ability to activate SREBP-1c and lipogenesis (Biddinger
et al., 2008; Brown and Goldstein, 2008). Enhanced lipogenesis
and the increasingly dyslipidemic state exacerbate the ‘‘selec-
tive insulin resistance,’’ causing more insulin release. We hypo-
thesize that PASK inhibition prevents this vicious cycle by
mitigating the toxic lipogenesis that can occur under conditions
of insulin resistance and hyperinsulinemia. We previously
showed that Pask!/! mice exhibit improved insulin sensitivity
and resistance to hepatic steatosis elicited by an HFD (Hao
et al., 2007). We now also show that treatment of HFrD-fed
rats with a PASK inhibitor completely normalized their elevated
expression of SREBP-1c target genes and hypertriglyceridemia.
Importantly, we observed no overt toxicity upon genetic
depletion of PASK (Pask!/! mice) or upon extended treatment
with PASK inhibitor doses that were 10- to 30-fold higher than
those required to elicit significant effects on lipogenic gene
expression and serum triglycerides. This treatment regimen
had no effect on body weight, even after 90 days of treatment.
It also had no effect on the expression of SREBP-1c or its target
genes in two other tissues of metabolic importance, skeletal
muscle, and adipose tissue. In contrast, inhibition of mTORC1
with rapamycin caused decreased lipogenesis in adipose tissue,
which was accompanied by decreased expression of SREBP-1
(Pereira et al., 2013). The selectivity of the effect of PASK inhibi-
tion is also in contrast to the phenotype observed for themajority
of mice lacking SREBP-1, which die in utero (Shimano et al.,
(E–G) Rat primary hepatocytes were treated with vehicle or BioE-1197 as in (D), followed by insulin as in Figure 1I, and the mRNA abundance of the indicated
genes was measured as in Figure 1I. Data shown are the average of n = 3 ± SEM. The value of the vehicle-treated/unstimulated group was set as one.
(H) Rat primary hepatocytes were treated and measured for 14C-acetate incorporation into lipids as in (D). Data shown are the average of n = 3 ± SD.
See also Figure S3.




1997b), whereas mice lacking PASK are viable. Therefore, we
conclude that PASK is not required for the basal activation of
SREBP-1 or for the activation of SREBP-1 in all tissues. Our
data suggest an important role for PASK in the hepatic activation
of SREBP-1c in response to feeding. However, it is possible that
PASK has functions in other tissue types that may contribute to
the beneficial effect on metabolism we observed upon PASK
inhibition. Nonetheless, this observation is of particular interest
in light of the potentially causal role that hepatic SREBP-1c
activation has been proposed to play in metabolic disease in
humans. Others have shown that genetic or pharmacological in-
hibition of SREBP maturation improves hepatic and whole-body
metabolism (Moon et al., 2012; Tang et al., 2011). We therefore
propose that SREBP-1c activation by PASK is an important
Figure 6. PASK Inhibition Decreases SREBP-1 Activity, Triglycerides, and Insulin Resistance in Animal Models
(A) Rats fed either an NCD or HFrD for 2 weeks were subjected to a once/day treatment with vehicle or the indicated dose of BioE-1115 by oral gavage for 1 week.
Following this regimen, the rats were fasted for 24 hr and then refed for 12 hr. Livers were harvested and qRT-PCR was performed for the indicated genes and
normalized to Cyclophilin A (n = 10/group). Data shown are the average ± SEM.
(B) Rats were maintained on an HF-HFrD for 18 weeks and treated with vehicle or the indicated dose of BioE-1115 as in (A) for the last 3 weeks. Livers were
harvested after rats were subjected to fast/refeeding as in (A). Whole-liver lysates and nuclear extracts were subjected to immunoblot to determine the abun-
dance of the precursor or mature form of SREBP-1 and the indicated control proteins. mpk: mg/kg.
(C) Triglycerides were measured in livers from the indicated treatment groups as described in (A) (n = 10/group).
(D–G) Serum TAG, cholesterol, glucose, and insulin were measured in animals treated as in (A).
(H) Calculated HOMA-IR values.
(I and J) Liver (I) and body (J) weights of the animals in (A). All data shown are the average ± SEM. See also Figures S4–S6.




feature of the mammalian metabolic syndrome and should be
explored as a therapeutic opportunity in humans.
EXPERIMENTAL PROCEDURES
Animals
Pask!/!mice were described previously (Hao et al., 2007). Age-matched male
WT and Pask!/! mice were maintained on either an NCD for 12 weeks or a
60% HFD for 8 weeks, from 8 to 10 weeks of age (60% fat by calories;
Research Diets). For fasting-refeeding studies, mice were either fasted for
24 hr or fasted for 24 hr and refed an NCD or HFD for the indicated time periods
before they were euthanized and their organs were harvested. All procedures
were approved by the Institutional Animal Care and Use Committee of the
University of Utah.
SDmale rats (Charles River Laboratories) were maintained on an HFrD (60%
fructose; Research Diets) or NCD for 2 weeks or on a high-fat and high-fruc-
tose diet (HF-HFrD, 60% high fat diet and 15% fructose drinking water) for
15 weeks before experiments were conducted. The rats were housed under
standard vivarium conditions (12 hr light/dark cycle) with water and chow ad
libitum. All studies were approved by the Institutional Animal Care and Use
Committee of the University of Utah and/or St. Louis University as appropriate.
Luciferase Assay
HepG2 cells were cotransfected with (1) pGPAT-Luc, pSCD-Luc, or pSRE-
Luc; (2) a construct expressing CMV-driven Renilla luciferase (Promega); or
(3) a pQCXIN-GFP, pcDNA3.1-2xFlag-mSREBP-1a, or pQCXIN-3xFlag-
pSREBP-1a construct, as indicated, using Lipofectamine LTX (Invitrogen),
according to the manufacturer’s instructions. Rat primary hepatocytes were
cotransfected with WT or mutant pSREBP-1c-Luc and Renilla luciferase using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
After transfection, the cells were serum-starved overnight, with additional
treatment of (1) vehicle, BioE-1197, or BioE-1428 and/or (2) 100 nM insulin
for 6 or 12 hr before harvest, as indicated. Firefly and Renilla luciferase were
assayed using the Dual-Reporter Luciferase Assay System (Promega).
Measurement of De Novo Lipogenesis
HepG2 cells or rat primary hepatocytes were treated with vehicle or 10 mM
BioE-1197 in serum-free media overnight. The next day, the cells were trans-
ferred to new media with vehicle or 30 mM BioE-1197 and 100 nM insulin for
6 hr as indicated, and were labeled with 10 mCi/ml [1-14C]-acetate (Perkin
Elmer) for the last 4 hr before harvest. The cells were washed twice with
PBS and then lysed in 0.5% Triton X-100. The lipid fraction was extracted
by adding chloroform andmethanol (v/v 2:1) followed by dH2O, with vortexing.
Samples were then centrifuged at 1,500 rpm for 15 min and the organic
(bottom) phase containing lipids was used to measure 14C incorporation on
a Beckman LS 6500 scintillation counter. The results were normalized to pro-
tein concentration of lysates.
ELISA
HEK293T cells were transfected with a pcDNA3.1-Flag-PASK (WT or kinase-
dead) construct using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. After 18 hr, the cells were reseeded into 96-well
plates in Dulbecco’s modified Eagle’s medium/1% fetal bovine serum. The
cells were then treated with DMSO or drug for 16 hr, followed by lysis in
0.2 ml lysis buffer (20 mM Na2HPO4, 0.5% Triton, 0.1% SDS, 0.02% azide,
1 mM NaF, 1 mM glycerophosphate, 1 mM Na3VO4). The lysates were then
applied to a MaxiSorb 96-well plate (Nunc) that was previously coated with
a-FLAG capture antibody (M2; Sigma), and blocked with 3% BSA (in 13
PBS). After incubation at 4"C for 1.5 hr, the plates were washed with high-
salt washing buffer (20 mM Na2HPO4, 0.5% Triton X-100, 0.1% SDS, 0.02%
NaN3, 0.1% BSA, and 1 M NaCl) followed by low-salt buffer (150 mM NaCl).
Then the plates were incubated for 2 hr with antibody to either phospho-Akt
substrate (9614; Cell Signaling) or hPASK (U2501), followed by high- and
low-salt buffer washes. Subsequently, the plates were incubated with horse-
radish peroxidase-conjugated secondary antibody for 1 hr and then washed
with high- and low-salt buffer and 13 PBS. The phospho-AKT substrate or
PASK antibody-dependent luminescence signal was assayed using the
LumiGLO chemiluminescent substrate system (KPL) according to the manu-
facturer’s instructions. The inhibition curve and IC50 were determined using
Prism software (GraphPad).
Chemicals and Dosing Formulations
BioE-1197, BioE-1428, and BioE-1115 were synthesized by Pharmaron. All
compounds were made up in a vehicle formulation of 0.5% methylcellulose
and 0.025% Tween-80 (Sigma) in ddH20. Dosages were calculated and
compounds were weighed and placed in a 15 ml glass homogenizer (Kimble
Chase) towhich vehiclewas added. The compoundswere ground to a fine sus-
pensionand transferred to ascrew-top tube.Thehomogenizerwas rinsed twice
with vehicle and then brought to the final volume. Compounds were made up
every 4–5 days based on the animals’ weight and stored at room temperature.
The animals were orally dosed once a day between 7 a.m. and 9 a.m.
BioE-1115 in the SD Diet-Induced Obesity Model
Male SD rats (n = 8–12) were obtained in this study with an average weight of
129.4 ± 0.63 g and were maintained on an HFrD for 2 weeks or on an HF-HFrD
for 15 weeks prior to experimentation. The rats were dosed by oral gavage
once a day for 7, 21, or 90 days at doses of 1, 3, 10, 30, and 100 mg/kg of
BioE-1115 or with vehicle. Body weights were taken every day for compound
formulation. The animals were fasted for 24 hr and refed for 12 hr prior to termi-
nation of the experiment. All animals received their respective compound
dosage 3 hr prior to termination. The animals were euthanized by CO2 asphyx-
iation, and cardiac puncture was performed for the final serum analysis. Liver
tissue was taken during necropsy, weighed, and snap-frozen in liquid N2.
Blood was centrifuged at 3,500 rpm for 10 min and serum was collected and
analyzed for insulin, glucose, cholesterol, and triglycerides using a Beckman
CX 5Pro (Beckman Coulter).
Statistical Analysis
Data are presented as mean ± SD unless otherwise indicated. A two-tailed
equal variance t test was used to compare differences and the null hypothesis
was rejected at the 0.05 level.
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Figure S1. PASK depletion leads to lower SREBP-1 activity in HepG2 cells, related to Figure 2.
(A) HepG2 cells were treated with scrambled or 3$6.-specific siRNA (siA, siB or siC). Cells were serum 
starved overnight, and mRNA levels of the indicated genes were measured by qRT-PCR and normalized to 
7XEXOLQ mRNA levels. Data shown are the average of n=3 ± SEM, with the Scr value set as 1. (B and C) 
3$6. silenced HepG2 cells were transfected with Gpat1-Luc (B) or SCD1-Luc (C) as well as Renilla lucifer-
ase (as a normalizing control).  Cells were then serum starved overnight, and firefly and Renilla luciferase 
were assayed using the Dual-Reporter Luciferase Assay System. Data shown are the average of n=3 ± SD, 
with the scr value set as 1.







Figure S2. Loss of PASK leads to suppression of 
SREBP-1 maturation, related to Figure 3.
(A) 3$6. silenced HepG2 cells expressing GFP, 3xFlag-
tagged precursor SREBP-1a or SREBP-1c were serum 
starved overnight and stimulated with 100nM insulin for 6 
h, as indicated. Whole cell lysate and nuclear extract were 
subjected to immunoblot for the phosphorylation state and 
abundance of the indicated proteins. (B and C) Mouse 
Insig1 and Insig2b mRNA level in normal chow (B) or high 
fat (C) diet-fed mouse liver was measured as in Figure 1. 
Data shown are the average of n=3 ± SEM, with the “WT fasted” value set as 1. (D) Top: SRE-Luc activity 
was measured in 3$6. silenced HepG2 cells co-transfected with a construct expressing GFP or mature or 
precursor SREBP-1a along with SRE-Luc. Data shown are the average of n=3 ± SD, with the scr value set as 
1. Bottom: Following luciferase assay, cell lysates were subjected to immunoblot for the phosphorylation state 
and abundance of the indicated proteins. (E) Rat primary hepatocytes were transfected with plasmids 
expressing luciferase driven by either wild-type mouse 65(%3F promoter, or a mutant promoter with 
disrupted SRE. Cells were then treated with BioE-1197 and 100nM insulin as indicated. Firefly and Renilla 
luciferase were assayed. Duplicate plates were prepared for each condition, and each plate was assayed in 










Figure S3. PharmacologicDO inhibition of PASK leads to lower SREBP-1 activity, related to Figure 4 and 5.
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Figure S4. Compound and transcripts levels in vehicle or BioE-1115 treated rat livers, 
related to Figure 6.
(A) Rats fed either normal chow or high-fructose diet for 2 weeks were subjected to once/day treat-
ment with vehicle or the indicated dose of BioE-1115 by oral gavage for one week. Following this 
regimen, rats were fasted for 24 h and then refed for 12 h. Plasma BioE-1115 levels were measured 
(n=10/group). (B-L) Livers were harvested from animals in (A) and qRT-PCR was performed as 











Figure S5. Effect of long-term PASK inhibition in animal models, related to Figure 6.
(A) Rats were treated and analyzed as in Figure 6A, except they were subjected to once/day treatment 
with vehicle or the indicated dose of BioE-1115 by oral gavage for 90 days.  Livers were harvested and 
T573&5ZDVSHUIRUPHGIRUWKHLQGLFDWHGJHQHVDQGQRUPDOL]HGWR&\FORSKLOLQ$QJURXS%(
Serum TAG and glycated hemoglobin (HbA1c) were measured in the animals from (A) at either 45 







Figure S6. mRNA levels of various genes in vehicle or BioE-1115 treated rat fat and muscle, 
related to Figure 6.
Rats fed either normal chow or high-fructose diet for 2 weeks were subjected to once/day treatment with 
vehicle or the indicated dose of BioE-1115 by oral gavage for 90 days. Following this regimen, rats were 








Table S1. Hepatic mRNA levels of various genes in HFD-fed wild-type and PDVN--mice. 
Gene 
Fast Refed 
WT KO WT KO 
mSrebp-1a 0.89±0.19 0.70±0.12 1.40±0.08 1.10±0.08* 
mSrebp-1c 0.70±0.20 0.42±0.09 1.53±0.15 0.90±0.14* 
mSrebp-2 0.83±0.14 0.91±0.12 1.17±0.11 1.17±0.06 
mHmgcs1 0.56±0.07 0.94±0.31 1.65±0.30 1.77±0.35 
mHmgcr 0.45±0.04 0.74±0.09** 1.34±0.15 1.18±0.17 
 
Wild-type and PDVN-/- mice on the C57/BL6J background were maintained on a 60% high-fat 
diet (HFD) for 8 weeks (n≥4/group). Before harvesting, mice were fasted for 24 h, or fasted 
for 24 h and refed a 60% HFD for 12 h. Livers were harvested and mRNA levels of indicated 
genes were measured by qRT-PCR and normalized to Cyclophilin A mRNA levels. Data 








2h 6h 8h 
WT KO WT KO WT KO WT KO 
mSrebp-1a 0.55±0.09 0.58±0.01 0.97±0.09 0.96±0.04 1.16±0.22 0.86±0.02 1.14±0.15 0.82±0.04 
mSrebp-1c 0.26±0.01 0.27±0.02 0.70±0.24 0.72±0.23 0.93±0.27 1.19±0.14 2.51±0.88 1.49±0.26 
mSrebp-2 0.46±0.04 0.50±0.17 0.77±0.14 0.62±0.05 1.16±0.10 0.85±0.04* 1.00±0.11 0.78±0.08 
mHmgcs1 0.36±0.09 0.22±0.03 0.53±0.24 0.36±0.03 1.89±0.16 1.58±0.32 2.46±0.28 1.98±0.25 
mHmgcr 0.18±0.03 0.14±0.02 0.73±0.27 0.46±0.05 3.03±0.34 1.50±0.27* 2.56±0.25 1.26±0.02** 
 
Wild-type and PDVN-/- mice on the C57/BL6J background were maintained on a normal chow diet 
(NCD) for 12 weeks. Before harvesting, mice were fasted for 24 h, or fasted for 24 h and refed aQ 
NCD for indicated time periods. Livers were harvested and mRNA levels of indicated genes were 
measured by qRT-PCR and normalized to Cyclophilin A mRNA levels. Data shown are the 
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In this dissertation, we have identified PASK as a novel regulator of 
SREBP-1c, the master transcription factor that drives the lipogenic program in 
liver in response to feeding and insulin signaling. Using genetic and 
pharmacological approaches, we showed that PASK is required for the 
proteolytic maturation of SREBP-1c in response to feeding and insulin 
stimulation. Genetic depletion and pharmacological inhibition of PASK result in 
lower levels of mature SREBP-1, decreased expression of its lipogenic target 
genes and reduced lipid production in cultured cells and in rodent livers. 
Interestingly, the expression of PASK itself is also upregulated in response to 
feeding and insulin, consistent with its function in promoting lipogenesis. 
As the master transcriptional regulator of the lipogenic program, 
hyperactivation of SREBP-1c is causally linked to hepatic steatosis (NAFLD), 
hypertriglyceridemia and other metabolic disorders. Metabolic diseases have 
become a new epidemic around world. Failure to properly maintain energy 
balance at the whole-body and cellular levels is at the heart of these diseases. 
Cellular energy balance is maintained via two well-characterized energy and 
nutrient sensors, AMP-activated protein kinase (AMPK) and mechanistic Target 
of Rapamycin (mTOR). AMPK senses low cellular energy levels and suppresses 
biosynthetic processes, whereas mTOR responds to nutrient abundance and 
stimulates biosynthetic processes. Thus, together, these two protein kinases 
function to coordinate cellular metabolism with nutrient environment and energy 
status. Dysreguation of AMPK and mTOR signaling pathways has been shown to 
play vital roles in the development of metabolic disorders. Interestingly, both 
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AMPK and mTOR target SREBP-1c to appropriately regulate fatty acid and 
triglyceride biosynthesis. PASK is proposed as a nutrient-responsive metabolic 
regulator. Our results show that PASK expression is induced by feeding in liver, 
and it regulates hepatic lipogenesis via SREBP-1c as well. Intriguingly, 
administration of a PASK inhibitor not only corrects hepatic and whole-body 
dyslipidemia, but also improves insulin sensitivity and other metabolic parameters 
in diet-induced obese rats, indicating that PASK is a potential therapeutic target 
for metabolic diseases. 
While the work described in Chapter 2 has furthered our understanding of 
the physiological function of PASK, it has raised several interesting questions as 
well. For example, the mechanism(s) whereby PASK regulates SREBP-1c 
maturation, as well as the precise placement of PASK within the insulin-SREBP-
1c regulatory pathway, still remains elusive. In the appendices, we present two 
preliminary studies suggesting that PASK may activate SREBP-1c maturation by 
directly phosphorylating the precursor form, and PASK may act as a downstream 
effector of mTORC1 in regulating SREBP-1 activity. 
Taken together, our work suggests an overall model where nutrients and 
insulin signaling potentially activates PASK through mTORC1 signaling. Upon 
activation, PASK stimulates SREBP-1 maturation potentially via direct 
phosphorylation, which in turn leads to increased expression of the lipogenic 
enzymes and elevated lipid synthesis. As protein kinases represent one of the 
largest families of druggable targets, our findings provide a potential therapeutic 








PHOSPHORYLATION OF SREBP-1C BY PASK – A POTENTIAL 




Sterol regulatory element binding protein 1c (SREBP-1c) is a transcription 
factor that plays crucial roles in regulating lipid metabolism in liver (Horton et al., 
2002). Upon activation by feeding and insulin signaling, SREBP-1c stimulates the 
transcription of genes involved in fatty acid and triglyceride biosynthesis, thus 
promoting the conversion of dietary nutrients into lipid for storage (Xu et al., 
2013). Hyperactivation of SREBP-1c has been shown to play a causal role during 
the development of various metabolic disorders, such as hepatic steatosis, 
hypertriglyceridemia and insulin resistance (Brown and Goldstein, 2008). 
As the master transcriptional regulator of the lipogenic program, SREBP-
1c is tightly regulated at multiple levels. One unique posttranslational regulatory 
step is the proteolytic maturation of the membrane-bound precursor SREBP-1c 
into its transcriptionally active mature form (Xiao and Song, 2013). SREBP-1c is 
first synthesized as a transcriptionally inert precursor form that resides on the 
endoplasmic reticulum (ER) membrane. Precursor SREBP-1c forms a complex 
with SREBP cleavage activating protein (SCAP), and is retained in the ER by an 
ER membrane resident protein insulin induced gene (Insig). Upon stimulation, 
Insig protein dissociates from SCAP, which allows SCAP to interact with the 
COPII trafficking machinery. As a result, precursor SREBP-1c migrates to the 
Golgi membrane, where it undergoes proteolytic cleavages to liberate the N-
terminal transcriptionally active fragment of the protein known as mature SREBP-
1c. Mature SREBP-1c then enters the nucleus to activate the transcription of its 
lipogenic target genes. 




signaling (Ye and DeBose-Boyd, 2011). This process is primarily mediated by the 
canonical phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway, and is partially 
dependent on mechanistic target of rapamycin complex 1 (mTORC1), a major 
downstream effector of Akt (Porstmann et al., 2008; Yecies et al., 2011). 
Alternatively, Akt can also activate SREBP-1c maturation in an mTORC1-
independent manner (Yecies et al., 2011). Akt suppresses the Insig2a mRNA 
level by promoting its degradation via the 3’ untranslated region (3’ UTR), 
resulting in enhanced SREBP-1 maturation (Yellaturu et al., 2009b). Additionally, 
Akt also induces serine and threonine phosphorylation of precursor SREBP-1c 
(Yellaturu et al., 2009a). This phosphorylation event causes the SCAP/SREBP-
1c complex to associate with the COPII trafficking machinery with higher affinity, 
thus promoting its ER-to-Golgi translocation and proteolytic maturation. The 
detailed mechanisms whereby insulin/Akt promotes Insig2a downregulation and 
SREBP-1c phosphorylation, however, remain poorly understood.  
PAS kinase (PASK) is an evolutionally conserved serine/threonine kinase 
that functions as a metabolic regulator in response to nutrient and other signals 
(Hao and Rutter, 2008). Previously we have shown that PASK promotes hepatic 
lipogenesis in response to feeding and insulin signaling by activating SREBP-1c 
maturation (Wu et al., 2014). However, the detailed mechanism whereby PASK 
regulates SREBP-1c maturation remains unclear. Since the effect of PASK on 
SREBP-1c maturation is downstream of insulin signaling, we decided to examine 
the involvement of PASK in the known regulatory pathways linking insulin and 




As mentioned earlier, downregulation of Insig2a is required for the 
induction of SREBP-1c maturation upon insulin stimulation (Yecies et al., 2011; 
Yellaturu et al., 2009b). Previously we have observed that PASK depletion had 
no effect on Insig2a mRNA levels, suggesting that PASK does not regulate 
SREBP-1c maturation by suppressing Insig2a. However, the Insig2a mRNA level 
does not always correlate with the Insig2 protein level, as evidenced by the 
downregulation of Insig2a transcripts, but accumulation of Insig2 protein in livers 
from liver-specific insulin receptor knockout (LIRKO) mice upon feeding (Haas et 
al., 2012). To determine if PASK can regulate Insig2 at the protein level, we 
examined the abundance of Insig2 protein upon PASK inhibition in cultured cells 
and in vivo. No significant changes in the Insig2 protein level were observed in 
PASK-silenced HepG2 cells (Figure A-1A) or liver from rats treated with PASK 
inhibitor BioE-1115 (Figure A-1B), although both of these treatments suppress 
SREBP-1 maturation (Wu et al., 2014). These results further support the notion 
that the effect of PASK on SREBP-1 maturation is not mediated by Insig2a. 
In addition to modulating the Insig2a level, insulin can also stimulate 
SREBP-1c maturation by promoting its phosphorylation and association with 
COPII vesicles (Yellaturu et al., 2009a). The kinase that is responsible for this 
phosphorylation has not been identified. Because of the serine/threonine kinase 
activity of PASK, as well as the presence of the PASK consensus 









Figure A-1. PASK inhibition has no effect on the Insig2 protein level. (A) 
HepG2 cells were treated with scrambled or PASK-specific siRNA (siA or siB). 
Cells were then serum starved overnight and stimulated with 100nM insulin for 6 
h, as indicated. Whole-cell lysates were subjected to immunoblot to determine 
the abundance of the indicated proteins. (B) Rats were maintained on high-fat 
and high-fructose diet for 18 weeks, and were subjected to once/day treatment 
with vehicle or the indicated dose of BioE-1115 by oral gavage for the last 3 
weeks. Following this regimen, rats were fasted for 24 h and then refed for 12 h. 
Livers were harvested from these animals, and whole liver lysate were subjected 























phosphorylate SREBP-1c to stimulate its maturation in response to insulin 
signaling. To test this hypothesis, we first examined whether PASK could 
physically associate with SREBP-1c. As shown in Figure A-2, endogenous PASK 
was co-immunoprecipitated with Flag-tagged precursor SREBP-1c as well as 
mature SREBP-1c, although to a lesser extent. This preference for the precursor 
form in PASK interaction is interesting given its function in regulating SREBP-1c 
maturation. We then determined if PASK could directly phosphorylate SREBP-1c 
by performing an in vitro kinase assay. PASK purified from baculovirus-infected 
insect cells was incubated with recombinant mature SREBP-1c purified from 
transfected HEK293T cells in the presence of ATP. As shown in Figure A-3, 
mature SREBP-1c was efficiently phosphorylated by PASK. This phosphorylation 
was abolished by adding a PASK-specific inhibitor BioE-1197 to the reaction. 
These results indicate that SREBP-1c is a direct substrate of PASK in vitro. 
In summary, here, we have presented preliminary data suggesting that 
upon insulin stimulation PASK activates SREBP-1c maturation, potentially by 
direct phosphorylation. Phosphorylation of SREBP-1c has been demonstrated as 
an important regulatory mechanism for its maturation. For example, AMP-
activated protein kinase (AMPK) phosphorylates mature SREBP-1c at serine 
residue 372 (Li et al., 2011). Serine to alanine mutation of this phosphorylation 
site in the precursor form abolished the inhibitory effect of AMPK on SREBP-1c 
maturation. On the other hand, elevated serine and threonine phosphorylation of 












Figure A-2. PASK co-immunoprecipitates with SREBP-1c. Flag-tagged YFP, 
precursor or mature hSREBP-1c was expressed in HEK293T cells. Flag 
immunoprecipitates were subjected to immunoblot to examine the co-
precipitation of PASK (Left). Input represents 5% of the total cell lysate used for 






3xFlag-m-1c - - + - - + 
3xFlag-p-1c - + - - + - 
3xFlag-YFP + - - + - - 













Figure A-3. PASK phosphorylates SREBP-1c in vitro. In vitro kinase assay 
was performed using hPASK purified from baculoviral-infected insect cells and 
mature hSREBP-1c purified from HEK293T cells in the presence or absence of 
BioE-1197. The reaction mixture was subjected to immunoblot to examine the 
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promotes its translocation to the Golgi for proteolytic maturation (Yellaturu et al., 
2009a). We showed that PASK can directly phosphorylate SREBP-1c in vitro. 
Although the mature SREBP-1c, which is the N-terminal fragment of the protein, 
was used in the kinase assay, it is likely that PASK can phosphorylate the 
precursor SREBP-1c as well. This is because the N-terminal portion of SREBP-
1c is localized on the cytosolic side of the ER membrane (Brown and Goldstein, 
1997; Hua et al., 1995), and is therefore accessible to PASK. Future studies will 
be aimed toward identifying the PASK phosphorylation site(s) on SREBP-1c, as 
well as examining the effect of such phosphorylation event(s) on SREBP-1c 
maturation. 
 
A.1 Material and Methods 
A.1.1 Animals 
Sprague-Dawley (SD) male rats (Charles River Laboratories) were housed 
under standard vivarium conditions (12 h light/dark cycle) with water and chow ad 
libitum. All studies were approved by the Institutional Animal Care and Use 
Committee guidelines of the University of Utah and/or St. Louis University as 
appropriate. 
Rats were maintained on high-fat and high-fructose diet for 18 weeks, and 
were treated with vehicle or indicated dose of BioE-1115 as previously described 
for the last 3 weeks (Wu et al., 2014). Animals were euthanized by CO2 
asphyxiation. Liver tissue was taken during necropsy, weighed and snap frozen 





A.1.2 Cell Lines and Cell Culture 
HepG2 and HEK293T cells were obtained from ATCC. HepG2 cells were 
maintained in 1:1 DMEM/F-12 (HyClone) supplemented with 10% FBS and 1% 
penicillin/streptomycin (Sigma). HEK293T cells were maintained in DMEM 
(Mediatech) supplemented with 10% FBS and 1% penicillin/streptomycin. 
 
A.1.3 Plasmids and Plasmid Constructions 
N-terminally Flag-tagged precursor or mature SREBP-1c was cloned from 
human SREBP-1 cDNA (BC057388; Open Biosystems) and ligated into the 
pQCXIN retroviral vector to generate pQCXIN-3xFlag-p-hSREBP-1c or pQCXIN-
3xFlag-m-hSREBP-1c. Both constructs were verified by sequencing. pcDNA3.1-
2xFlag-mSREBP-1c, a plasmid expressing the mature form of human SREBP-1c, 
was obtained from Addgene (plasmid # 26802). pSRE-Luc, a plasmid containing 
the hamster HMG-CoA synthase sterol regulatory elements fused to luciferase 
cDNA, was a kind gift from Dr. Timothy F. Osborne (Sanford-Burnham Medical 
Research Institute). 
 
A.1.4 PASK Silencing 
HepG2 cells were transfected with scrambled (Allstars negative control 
siRNA, Qiagen) or human PASK-specific siRNAs (Qiagen) using HiPerFect 
transfection reagent (Qiagen), according to the manufacturer’s instructions. Cells 





A.1.5 Immunoprecipitation and Immunoblot 
For co-immunoprecipitation experiments, HEK293T cells were transfected 
with Flag-tagged YFP, precursor or mature hSREBP-1c using Lipofectamine 
2000 (Invitrogen), according to the manufacture’s instructions. Cells were then 
lysed in lysis buffer (40 mM HEPES pH 7.4, 150 mM NaCl, 2 mM EDTA, 2mM 
EGTA, 2mM KCl, 1% CHAPS and protease inhibitors). After centrifugation, Flag-
tagged YFP or hSREBP-1c was immunoprecipitated using anti-Flag M2 affinity 
gel (Sigma-Aldrich A2220). For in vitro kinase assay, Flag-tagged mature 
hSREBP-1c was expressed and purified from HEK293T cells as described 
previously (Kikani et al., 2010). 
For immunoblot, HepG2 cell lysates were prepared by directly dissolving 
cells in 1X SDS sample buffer. Liver lysate were prepared as described 
previously (Wu et al., 2014). Protein samples were then separated by SDS-
PAGE and transferred to nitrocellulose for blocking and incubation with primary 
antibody and secondary antibody conjugated with infrared dyes for detection by 
the Odyssey system (LI-COR). Primary antibodies were obtained from the 
following sources: anti-hPASK (U2501) as previously described; anti-Flag (M2) 
and anti-bActin (A5441) from Sigma; anti-Insig2 (Ab86415) from Abcam. 
 
A.1.6 In Vitro Kinase Assay 
Flag-tagged mature hSREBP-1c was purified from HEK293T cells as 
described above. Kinase assay was performed as described previously (Kikani et 




baculoviral infected insect cells in the presence or absence of BioE-1197. 
Samples were then separated by SDS-PAGE and transferred to nitrocellulose for 
autoradiography and immunoblot. 
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Insulin is a key anabolic hormone that promotes the uptake and storage of 
excess nutrients in metabolic tissues, such as liver, muscle and white adipose 
tissue (Samuel and Shulman, 2012). In liver, the major actions of insulin are to 
suppress gluconeogenesis while stimulating glycogen synthesis and lipogenesis. 
The pro-lipogenesis effect of insulin is primarily mediated by Akt, and is 
dependent on sterol regulatory element binding protein 1c (SREBP-1c), the 
master transcriptional regulator of lipid metabolism in liver. In response to insulin 
signaling, SREBP-1c activates the transcription of genes involved in fatty acid 
and triglyceride biosynthesis, thereby promoting the production of triglyceride 
from dietary nutrients for energy storage.  
SREBP-1c is activated by insulin/Akt at both transcriptional and 
posttranslational levels (Krycer et al., 2010), but the exact mechanism underlying 
this regulatory effect is not completely understood yet. Growing evidence 
indicates that mechanistic target of rapamycin complex 1 (mTORC1), a protein 
kinase complex activated by Akt, plays an essential role in this pathway. Upon 
activation, mTORC1 promotes (1) the transcription of SREBP-1c (Li et al., 2010); 
(2) the posttranslational proteolytic maturation of precursor SREBP-1 to generate 
the transcriptionally active mature form of the protein (Owen et al., 2012; 
Porstmann et al., 2008; Yecies et al., 2011); and (3) the accumulation of mature 
SREBP-1 in the nucleus (Peterson et al., 2011). Genetic and pharmacological 
inhibition of mTORC1 suppressed SREBP-1 activity and lipogenesis both in vitro 
and in vivo (Owen et al., 2012; Peterson et al., 2011; Porstmann et al., 2008; 






remain largely unclear, and only few downstream effectors have been identified. 
p70 ribosomal S6 kinase (S6K), a kinase directly activated by mTORC1, has 
been reported to mediate mTORC1’s effect on SREBP-1 maturation under some 
but not all conditions (Duvel et al., 2010; Lewis et al., 2011; Owen et al., 2012), 
suggesting an alternative mechanism distinct from S6K activation. 
We have previously shown that PASK activates SREBP-1 by promoting its 
maturation in response to insulin signaling (Wu et al., 2014). However, the 
precise placement of PASK within the insulin-SREBP-1c regulatory pathway is 
still not clear. Interestingly, unpublished data from our lab indicate that PASK 
activity is induced by insulin stimulation in an mTORC1-dependent manner. 
Moreover, mTORC1 directly binds PASK and phosphorylates it at multiple sites 
to promote its activity. These results raise a hypothesis that in response to insulin 
signaling, PASK may function downstream of mTORC1 to activate SREBP-1. 
To test this hypothesis, we first sought to determine whether PASK acted 
in the same pathway as mTORC1 to regulate SREBP-1. To test this, we 
examined the individual and combined effects of PASK silencing and mTORC1 
inhibition by rapamycin on insulin-induced SREBP-1 activation in HepG2 cells. 
SREBP-1 activity was measured using a luciferase reporter that contains isolated 
SREBP binding sites in its promoter region. Consistent with our previous 
observation, insulin treatment caused a significant increase in SREBP-1 activity 
in control cells (Figure B-1). This increase was partially or completely suppressed 
by PASK knockdown or rapamycin treatment, indicating that inhibition of PASK or 










Figure B-1. PASK and mTORC1 function in a linear pathway to activate 
SREBP-1. HepG2 cells were treated with scrambled or PASK-specific siRNA 
(siB), and then transfected with SRE-Luc reporter. Cells were serum starved 
overnight in the presence or absence of rapamycin, and then stimulated with 
100nM insulin for 6 h, as indicated. Firefly and Renilla luciferase were assayed 
using the Dual-Reporter Luciferase Assay System. Data shown are the average 







Interestingly, combined inhibition of PASK and mTORC1 did not further reduce 
SREBP-1 activity compared to PASK silencing alone, suggesting that PASK and 
mTORC1 function in a linear pathway to regulate SREBP-1 activation.  
To directly test whether PASK is an effector downstream of mTORC1 in 
regulating SREBP-1 activity, we examined the effect of PASK inhibition on 
SREBP-1 activity upon mTORC1 activation. As shown in Figure B-2, 
overexpression of Rheb, a small GTPase that activates mTORC1 (Sarbassov et 
al., 2005), greatly induced SREBP-1 activity. This induction was reduced by 60% 
in PASK inhibitor BioE1197-treated cells, indicating that PASK is required for the 
full activation of SREBP-1 induced by mTORC1. 
Our preliminary results suggest that PASK is a major downstream effector 
of mTORC1 in activating SREBP-1. mTORC1 activates SREBP-1 at multiple 
levels (Xu et al., 2013). Given the critical role of PASK in regulating SREBP-1 
maturation, it is conceivable that PASK may mediate the effect of mTORC1 on 
SREBP-1 maturation. Further studies will need to be done to directly examine 
SREBP-1 maturation upon manipulation of PASK and mTORC1.  
Hyperactivation of SREBP-1c lies at the heart of a pathological condition 
in liver called “selective insulin resistance” (Brown and Goldstein, 2008). Under 
this condition, insulin fails to activate glycogen synthesis and suppress 
gluconeogenesis in liver due to impaired insulin signaling. However, the SREBP-
1c-mediated lipogenesis remains fully active, which leads to the combination of 
hyperglycemia and hypertriglyceridemia observed in diabetic patients. One 












Figure B-2. PASK is a downstream effector of mTORC1 in regulating 
SREBP-1. HepG2 cells were transfected with empty vector or wild-type Rheb 
along with SRE-Luc reporter. Cells were then treated overnight with vehicle or 50 
µM BioE-1197 in media with 2% FBS, as indicated. Firefly and Renilla luciferase 
were assayed using the Dual-Reporter Luciferase Assay System. Data shown 







activated by stimuli other than insulin. It is well known that, in addition to insulin, 
mTORC1 can also be activated by glucose and amino acids, two nutrients that 
are highly abundant under insulin resistant conditions (Zoncu et al., 2011). 
Moreover, mTORC1 has been shown to selectively regulate the expression of 
SREBP-1c and its lipogenic target genes in liver, while having no effect on the 
expression of gluconeogenic genes (Li et al., 2010). Therefore, it is possible that 
under insulin resistant conditions, excess nutrients lead to the continuous 
activation of mTORC1, which in turn promotes SREBP-1c activity and 
lipogenesis, eventually resulting in hepatic and whole-body dyslipidemia. Our 
data suggest that PASK is a new link in the mTORC1-SREBP-1 pathway, and 
may play a role in promoting the development of selective insulin resistance in 
liver. 
In addition to metabolic diseases, aberrant activation of mTORC1 has also 
been connected to the initiation and progression of cancer (Zoncu et al., 2011). 
The effect of mTORC1 on tumorigenesis is partly attributed to its ability to 
promote metabolic reprogramming of cancer cells to support their rapid growth 
and proliferation (Duvel et al., 2010). One important aspect of such 
reprogramming is elevated lipogenesis due to the increased demand for 
membrane synthesis during cell growth and proliferation. Hyperactivation of 
mTORC1 has been shown to render tumor cells addicted to exogenous lipids 
under hypoxic conditions where de novo lipogenesis is reduced (Young et al., 
2013). Interestingly, it has been demonstrated that SREBP-1c as well as its 






synthase (FASN), are upregulated in a wide range of cancers, and are required 
for cancer cell growth and survival (Guo et al., 2014). Since PASK is potentially 
an intermediate regulator in the mTORC1-SREBP-1c pathway, it is tempting to 
speculate that PASK inhibition may prove valuable for cancer treatment.  
 
B.1 Material and methods 
B.1.1 Cell Lines and Cell Culture 
HepG2 and HEK293T cells were obtained from ATCC. HepG2 cells were 




pHAGE-CMV-Rheb-IRES-eGFP-W, a plasmid expressing wild-type human 
Rheb, was obtained from Addgene (Plasmid #32519). pSRE-Luc, a plasmid 
containing the hamster HMG-CoA synthase sterol regulatory elements fused to 
luciferase cDNA, was a kind gift from Dr. Timothy F. Osborne (Sanford-Burnham 
Medical Research Institute). 
 
B.1.3 PASK Silencing 
HepG2 cells were transfected with scrambled (Allstars negative control 
siRNA, Qiagen) or human PASK-specific siRNAs (Qiagen) using HiPerFect 
transfection reagent (Qiagen), according to the manufacturer’s instructions. Cells 







B.1.4 Luciferase Assay 
HepG2 cells were cotransfected with (1) pSRE-Luc; (2) a construct 
expressing CMV-driven Renilla luciferase (Promega); (3) pHAGE-CMV-Rheb-
IRES-eGFP-W construct, as indicated, using Lipofectamine LTX (Invitrogen), 
according to the manufacture’s instructions. After transfection, cells were (1) 
serum-starved overnight in the presence of 20 nM rapamycin, followed by 100 
nM insulin for 6 h before harvest; or (2) treated overnight with vehicle or 50 µM 
BioE-1197 in DMEM/F-12 with 2% FBS. Firefly and Renilla luciferase were 
assayed using the Dual-Reporter Luciferase Assay System (Promega). 
 
B.1.5 Statistical Analysis 
Data are presented as mean ± standard deviation unless otherwise 
indicated. A two-tailed equal variance t-test was used to compare differences, 
and the null hypothesis was rejected at the 0.05 level.  
 
B.2 References 
Brown, M.S., and Goldstein, J.L. (2008). Selective versus total insulin resistance: 
a pathogenic paradox. Cell Metabolism 7, 95-96. 
Duvel, K., Yecies, J.L., Menon, S., Raman, P., Lipovsky, A.I., Souza, A.L., 
Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010). Activation of a 
metabolic gene regulatory network downstream of mTOR complex 1. Molecular 
Cell 39, 171-183. 
Guo, D., Bell, E.H., Mischel, P., and Chakravarti, A. (2014). Targeting SREBP-1-







Krycer, J.R., Sharpe, L.J., Luu, W., and Brown, A.J. (2010). The Akt-SREBP 
nexus: cell signaling meets lipid metabolism. Trends in Endocrinology and 
Metabolism: TEM 21, 268-276. 
Lewis, C.A., Griffiths, B., Santos, C.R., Pende, M., and Schulze, A. (2011). 
Genetic ablation of S6-kinase does not prevent processing of SREBP1. 
Advances in Enzyme Regulation 51, 280-290. 
Li, S., Brown, M.S., and Goldstein, J.L. (2010). Bifurcation of insulin signaling 
pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not 
inhibition of gluconeogenesis. Proceedings of the National Academy of Sciences 
of the United States of America 107, 3441-3446. 
Owen, J.L., Zhang, Y., Bae, S.H., Farooqi, M.S., Liang, G., Hammer, R.E., 
Goldstein, J.L., and Brown, M.S. (2012). Insulin stimulation of SREBP-1c 
processing in transgenic rat hepatocytes requires p70 S6-kinase. Proceedings of 
the National Academy of Sciences of the United States of America 109, 16184-
16189. 
Peterson, T.R., Sengupta, S.S., Harris, T.E., Carmack, A.E., Kang, S.A., 
Balderas, E., Guertin, D.A., Madden, K.L., Carpenter, A.E., Finck, B.N., et al. 
(2011). mTOR complex 1 regulates lipin 1 localization to control the SREBP 
pathway. Cell 146, 408-420. 
Porstmann, T., Santos, C.R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, 
J.R., Chung, Y.L., and Schulze, A. (2008). SREBP activity is regulated by 
mTORC1 and contributes to Akt-dependent cell growth. Cell Metabolism 8, 224-
236. 
Samuel, V.T., and Shulman, G.I. (2012). Mechanisms for insulin resistance: 
common threads and missing links. Cell 148, 852-871. 
Sarbassov, D.D., Ali, S.M., and Sabatini, D.M. (2005). Growing roles for the 
mTOR pathway. Current Opinion in Cell Biology 17, 596-603. 
Wu, X., Romero, D., Swiatek, W.I., Dorweiler, I., Kikani, C.K., Sabic, H., Zweifel, 
B.S., McKearn, J., Blitzer, J.T., Nickols, G.A., et al. (2014). PAS kinase drives 
lipogenesis through SREBP-1 maturation. Cell Reports 8, 242-255. 
Xu, X., So, J.S., Park, J.G., and Lee, A.H. (2013). Transcriptional control of 
hepatic lipid metabolism by SREBP and ChREBP. Seminars in Liver Disease 33, 
301-311. 
Yecies, J.L., Zhang, H.H., Menon, S., Liu, S., Yecies, D., Lipovsky, A.I., Gorgun, 






hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and 
independent pathways. Cell Metabolism 14, 21-32. 
Young, R.M., Ackerman, D., Quinn, Z.L., Mancuso, A., Gruber, M., Liu, L., 
Giannoukos, D.N., Bobrovnikova-Marjon, E., Diehl, J.A., Keith, B., et al. (2013). 
Dysregulated mTORC1 renders cells critically dependent on desaturated lipids 
for survival under tumor-like stress. Genes & Development 27, 1115-1131. 
Zoncu, R., Efeyan, A., and Sabatini, D.M. (2011). mTOR: from growth signal 
integration to cancer, diabetes and ageing. Nature Reviews Molecular Cell 
biology 12, 21-35. 
 
